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ABSTRACT

Assessment and Mechanisms of Autonomic Function in Health
and Disease: A Role of Central Rho Kinase
Peter Ricci Pellegrino
University of Nebraska Medical Center, 2016
Supervisor: Irving H. Zucker, Ph.D.
The autonomic nervous system is a master regulator of homeostasis, and the conviction
that autonomic outflow is important on a patient-by-patient, minute-to-minute basis in both health
and disease is the motivation for this thesis. The dissertation explores three aims that advance our
understanding of the autonomic nervous system by elucidating the molecular mechanisms of
autonomic regulation, validating widely used techniques for autonomic assessment, and developing
and applying a new method to assess sympathetic vascular control.
The first aim of the dissertation was to investigate the role of the Rho kinase pathway as a
mediator of the autonomic effects of central angiotensin-II. This study was performed in conscious,
chronically instrumented rabbits that received intracerebroventricular infusions of angiotensin-II,
angiotensin-II with the specific Rho kinase inhibitor Fasudil, Fasudil alone, or a vehicle control
over two weeks. Baseline hemodynamics were assessed daily, and cardiac and global vasomotor
sympathetic tone was assessed by the hemodynamic response to autonomic blockers. AngiotensinII raised blood pressure and cardiac and global vasomotor sympathetic outflow in a Rho-kinase
dependent manner. In a separate cohort, renal sympathetic nerve activity was directly recorded and
sympathetic baroreflex sensitivity was assessed, providing clear evidence that angiotensin-II
increases renal sympathetic nerve activity and impairs baroreflex control thereof via a Rho kinasedependent mechanism. In summary, the pressor, sympatho-excitatory, and baroreflex dysfunction
caused by central angiotensin-II depend on Rho kinase activation.
The second aim was to investigate the relationship between measures of pulse rate
variability obtained by a chronically implanted arterial pressure telemeter with measures of heart
rate variability derived by the standard electrocardiogram and the ability of pulse rate variability to
reflect the autonomic contributions of heart rate variability. This study was conducted in conscious
rabbits chronically instrumented with epicardial leads and arterial pressure telemeters. The
autonomic contribution to pulse rate variability was assessed by pharmacological blockade, and the
intrinsic variability of pulse rate was assessed by ventricular pacing. This study showed that pulse
rate variability is a generally acceptable surrogate for heart rate variability for time- and frequencydomain measures, but the additional contribution of respiration to and the differing nonlinear
properties of pulse rate variability should be considered by investigators.
The third aim was to critically test the idea that the renal sympathetic nerves do not
participate in the physiological control of renal blood flow. This study was conducted in conscious
rabbits that underwent unilateral renal denervation and chronic instrumentation with arterial
pressure telemeters and bilateral renal blood flow probes. Using time-varying transfer function
analysis, this study showed active, rhythmic vasoconstriction of the renal vasculature with
baroreflex properties in normally innervated kidneys, consistent with sympathetic vasomotion,
which was absent in denervated kidneys. This refutes the long-held idea that sympathetic control
of the renal vasculature is not physiological and has important applications to the burgeoning field
of therapeutic renal denervation for cardiovascular disease.
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Cardiovascular Disease
Cardiovascular disease is arguably the most significant health problem in American
society1. Over 85 million American adults have at least one type of cardiovascular disease, and
cardiovascular disease has been the leading cause of death in the United States every year since
1900 with the exception of 1918 (when the influenza pandemic made infectious disease the leading
cause of death). In 2013, cardiovascular disease was the underlying cause of death in over 30% of
mortalities in the United States and played a role in over half of all deaths. The direct and indirect
costs of cardiovascular disease in the United States in 2009 totaled $313 billion (>2% of total GDP).
On a global scale, cardiovascular disease remains an eminent problem, accounting for over 17
million deaths (~31%) in 2013 and costing $863 billion in 2010 (~1.4% of global GDP).

Hypertension
Hypertension is the most common form of cardiovascular disease, with an estimated
prevalence of 80 million in the United States and nearly 1 billion worldwide in 20161. Clinically,
hypertension is diagnosed as a systolic blood pressure greater than or equal to 140 mm Hg or
diastolic blood pressure greater than or equal to 90 mm Hg at two or more visits although there is
growing momentum for the use of ambulatory blood pressure monitoring in diagnosis.
Hypertension predisposes to heart failure, stroke, myocardial infarction, and vascular disease.
Hypertension is the number one health risk factor in terms of its impact on disability-adjusted life
years, and thus the need for new prevention and treatment strategies is significant.
Despite the high clinical burden of hypertension, fundamental gaps in our understanding
of the disease remain, and over 90% of incident hypertension is of unknown etiology.
Pharmacotherapy is targeted at lowering blood pressure. Thiazide diuretics, calcium channel
blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers are the
mainstays of medical therapy, but other classes of drugs, including combined α1/β-blocking agents,
vasodilating β-blockers, central α2-adrenergic agonists, direct vasodilators, aldosterone receptor
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antagonists, adrenergic neuronal depleting agents, and loop diuretics, are also used2. On the horizon
are non-pharmacological therapies like baroreceptor stimulation, renal denervation, carotid body
denervation, and arteriovenous anastomosis for patients with treatment-resistant hypertension3–5.
Hypertensive patients are also strongly recommended to follow lifestyle like smoking cessation,
physical activity, weight loss, and eating a heahy diet low in sodium.

Renin-Angiotensin-Aldosterone System
The renin-angiotensin-aldosterone system (RAAS) is a humoral cascade important in the
control of arterial pressure and extracellular fluid volume. Dysregulation of the RAAS is common
in hypertension, and, as previously mentioned, the RAAS is an important therapeutic target in
hypertension as well as other cardiovascular and renal diseases.
The classical circulating RAAS cascade is controlled by the stimulus-induced release of
renin by juxtaglomerular cells in the kidney. Several stimuli are believed to induce renin secretion:
decreased afferent arteriolar pressure sensed by renal baroreceptors, decreases in NaCl flux sensed
by the macula densa, diminished negative feedback by angiotensin-II (AngII) itself directly on the
juxtaglomerular cells, and sympathetic β1-adrenergic stimulation of the juxtaglomerular cells. The
control of renin secretion is a key determinant of systemic RAAS activity as renin regulates the
rate-limiting step of the RAAS by cleaving angiotensinogen, secreted constitutively by the liver, to
form the biologically inert decapeptide angiotensin-I. Angiotensin-I is then cleaved to form the
biologically active octapeptide AngII by the membrane-bound angiotensin-converting enzyme,
which is found abundantly in vascular endothelial cells in the lung as well as microvillar brush
border cells in the kidney and neuroepithelial cells. AngII, the primary effector peptide of the
RAAS, increases blood pressure, expands the extracellular fluid volume, and stimulates the
synthesis of aldosterone by binding to the angiotensin type-1 receptor (AT1R) on different cells in
the body. Clinically, circulating RAAS activation can be assessed by measuring plasma renin
activity. About 60% of essential hypertensive patients have normal plasma renin activity, 15% have
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elevated plasma renin activity, and 25% have low plasma renin activity. Unfortunately, this
stratification is not useful for predicting the response to particular antihypertensive agents, and
plasma renin activity is not routinely measured in the assessment and management of patients with
essential hypertension.
In addition to the circulating RAAS, local tissue RAAS have been described in the heart,
blood vessels, kidney, adrenal glands, pituitary, adipose tissue, testes, ovaries, skin, carotid body,
and brain 6. Of particular relevance to this dissertation is the fact that all components of the RAAS
are present in the central nervous system, and the central RAAS is dysregulated in preclinical
models of hypertension7. Importantly, even in preclinical models in which plasma renin activity is
low, brain RAAS activity is elevated, suggesting that human hypertensive patients may show
similar incongruities between circulating and brain RAAS.
This summary only scratches the surface of the RAAS. Other components, including
prorenin, renin, angiotensin-III, angiotensin-IV, angiotensin(1-7), aldosterone, the prorenin
receptor, angiotensin type-2 receptor, angiotensin type-3 receptor, angiotensin type-4 receptor, the
Mas receptor, angiotensin-I converting enzyme 2, chymases, and neprilysin, are also important in
physiology and pathophysiology, but they are not central to this dissertation.

The Autonomic Nervous System
The autonomic nervous system is composed of two main branches: the sympathetic and
parasympathetic nervous systems. These limbs work in concert to maintain body homeostasis, or,
in disease, they may collude to foment dysregulation. All cells in the autonomic nervous system
are derived from neural crest cells that migrate via the ventromedial stream to aggregate into
ganglia and innervate their target tissues, providing homeostatic control of cardiovascular,
respiratory, gastrointestinal, urogenital, cutaneous, and adipose systems. These post-ganglionic
autonomic neurons are innervated by pre-ganglionic neurons in the central nervous system,
originating either from the lateral spinal cord or the brain stem. Sympathetic preganglionic neurons
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in turn receive input from brainstem areas like the rostral ventrolateral medulla (RVLM) and the
hypothalamus like the paraventricular nucleus (PVN). The central autonomic nuclei in the brain
stem and hypothalamus receive and integrate visceral input from baroreceptor, cardiac receptor,
chemoreceptor, and pulmonary mechanoreceptor afferents that terminate in the nucleus tractus
solitarii. The main neurotransmitter in both sympathetic and parasympathetic ganglia is
acetylcholine, which acts at the ganglionic-type nicotinic receptor to activate post-ganglionic
neurons. This ganglionic neurotransmission can be blocked by drugs like hexamethonium and
trimetaphan that antagonize the nicotinic receptors in the autonomic ganglia.
Pre-ganglionic neurons of the parasympathetic nervous system originate either cranially in
the brain stem or caudally in the lowest levels of the spinal cord. Pre-ganglionic neurons originating
in the brain stem travel along cranial nerves III, VII, IX, and X to innervate post-ganglionic neurons.
Cranial nerve X is particular in the respect that its pre-ganglionic neurons do not innervate cranial
ganglia but instead travel to ganglia innervating the thoracic and abdominal viscera. Everything
caudal to the midgut receives its parasympathetic innervation by pelvic splanchnic preganglionic
neurons whose cell bodies are located in the lateral gray horn at levels T12-L2 of the spinal cord.
Generally, the parasympathetic ganglia are very close to or located within the target organ, so the
preganglionic neurons have long axons compared to postganglionic neurons. The main postganglionic neurotransmitter in the parasympathetic nervous system is acetylcholine, which
mediates its effects by binding to muscarinic receptors. Briefly, parasympathetic outflow causes
miosis, ciliary muscle contraction, lacrimation, salivation, decreases in chronotropy, dromotropy,
and inotropy, bronchoconstriction, GI motility and secretion, micturition, and erection. The effects
of parasympathetic outflow can be blocked by muscarinic receptor blockade with atropine.
Preganglionic sympathetic fibers arise in the lateral gray horn of the thoracic and lumbar
segments of the spinal cord and synapse in sympathetic ganglia either in the sympathetic chain or
in prevertebral ganglia. Postganglionic neurons whose cell bodies reside in these sympathetic
ganglia then innervate target tissues. One notable exception is the chromaffin cells of the adrenal
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medulla, which are essentially specialized, secretory postganglionic neurons that release
norepinephrine and epinephrine into the circulation in response to preganglionic input. Briefly, the
sympathetic nervous system causes pupillodilation, increases in chronotropy, dromotropy.
Inotropy, and lusitropy, bronchodilation, GI stasis, urinary retention, uterine contraction and
relaxation, ejaculation, vasoconstriction and dilation, sweating, lipolysis, and glycogenolysis. The
main post-ganglionic neurotransmitter in the sympathetic nervous system is norepinephrine
although many other postganglionic neurotransmitters play specialized roles (e.g., acetylcholine
mediates sympathetic sudomotion). Blockade of sympathetic outflow with adrenergic receptor
blockers are a mainstay of therapy in cardiovascular disease. Importantly for studies in this thesis,
the effects of the sympathetic nervous system on chronotropy can be blocked by administration of
a beta-adrenergic blocker like metoprolol.
Closely tied to the motor arms of the autonomic nervous system are visceral afferents,
which sense physiologic and pathophysiologic mechanical and chemical stimuli and elicit reflex
autonomic responses. Visceral afferents are made up of finely myelinated Aβ and Aδ fibers and
unmyelinated C fibers that ascend to the CNS either via the vagus nerve or sympathetic pathways.
The nucleus tractus solitarii is a major relay center for visceral afferent traffic, and neurons in the
nucleus tractus solitarii project to important autonomic centers involved in the regulation of
sympathetic and parasympathetic outflow.
Several important autonomic reflexes are disturbed in experimental and clinical
cardiovascular

disease,

including

the

cardiopulmonary

baroreflex,

central/peripheral

chemoreceptor reflexes, the cardiac sympathetic afferent reflex, the exercise pressor reflex, and the
arterial baroreflex. The arterial baroreflex, a negative feedback loop that acutely buffers changes in
systemic perfusion pressure, is a focus of this dissertation. Afferents from baroreceptors in the
carotid sinus and aortic arch ascend in cranial nerves IX and X to the nucleus tractus solitarii. This
input then projects to the dorsal motor nucleus of the vagus and via the caudal ventrolateral medulla
to the rostral ventrolateral medulla. Preganglionic parasympathetic neurons in the dorsal motor
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nucleus of the vagus and presympathetic neurons in the rostral ventrolateral medulla form the
efferent limb of the reflex. The negative feedback is such that increases in blood pressure are
corrected by reflex decreases in heart rate, contractility, total peripheral resistance while decreases
in blood pressure are corrected by reflex increases in heart rate, contractility, and total peripheral
resistance and decreases in capacitance. This reflex is generally believed to exert tonic
sympathoinhibition, and the attenuation of baroreflex sensitivity in cardiovascular disease may
explain some of the sympatho-excitation observed in these patients.
In addition to the aforementioned brain stem areas important in autonomic control, several
regions of the forebrain merit mention because of their importance in this thesis. The first is the
subfornical organ (SFO), a circumventricular organ that mediates the autonomic response to both
circulating and intraventricular AngII8,9. The second is the paraventricular nucleus of the
hypothalamus (PVH), which is a key integrator of visceral stimuli and site of dysregulation in
cardiovascular disease10,11.

Sympatho-excitation in Hypertension
Measures of sympathetic outflow are generally elevated in patients with hypertension and
animal models of experimental hypertension; however, sympatho-excitation is not a sine qua non
of human hypertension as depicted by some clinical researchers. Studies in which muscle
sympathetic nerve activity (SNA) was directly recorded indicate that about one third of
hypertensive patients have normal sympathetic outflow12. Whether or not this heterogeneity in
sympathetic outflow reflects differences in etiology, is prognostic for disease sequelae, or could be
useful for management of care (e.g., predicting therapy responsiveness) remains to be elucidated.
The factors that have been implicated as causal factors in the sympatho-excitation of
hypertension are too numerous to discuss here. Two elements that are central to this dissertation
are baroreflex dysfunction and AngII. As discussed previously, the arterial baroreflex inhibits
sympathetic outflow in response to increased AP, restoring normal blood pressure levels. Patients
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with hypertension show baroreflex resetting to a higher AP although only certain types of
hypertensive patients (those with diastolic dysfunction) show blunted baroreflex gain13.
The capacity of AngII to increase sympathetic outflow was first described over forty years
ago

14,15

. Since then, studies have shown the autonomic centers of the brain, including the

circumventricular organs, nucleus tractus solitarii, and the rostral ventrolateral medulla, to be
important sites for the binding of central AngII9. In the central nervous system, AngII raises
sympathetic outflow and causes baroreflex resetting and blunting16. Over the last twenty years, the
intracellular mediators of AT1R signaling in AngII-mediated sympatho-excitation have become an
important topic of investigation 17.

RhoA/Rho kinase Pathway
RhoA is a ubiquitously expressed small GTPase that is involved in many fundamental
cellular processes. As a small GTPase, it is active in its GTP-bound form and becomes inactivated
when its intrinsic GTPase activity hydrolyzes bound GTP to GDP. RhoA is activated by various
guanine nucleotide exchange factors, deactivated by GTPase activating proteins. Cytosolic RhoA
is inactive, requiring isoprenylation for membrane localization, which can be inhibited by blocking
isoprenoid synthesis (e.g., by statins) or isoprenoid transferases. The guanine nucleotide
dissociation inhibitors prevent both dissociation of hydrolyzed GDP and membrane translocation,
blocking RhoA activation. In vitro studies with dominant positive and dominant negative RhoA
mutants have shown a role for RhoA in transcription, cell transformation, cell cycle progression,
vesicular trafficking, axonogenesis, dendritic spine formation, cell polarization, cell migration,
cell-cell adhesion, nitric oxide bioavailability, and generation of superoxide. Congruent with its
importance in these essential processes, RhoA knockout mouse embryos die very early. Rho kinase
is the main effector of RhoA. It exists in two isoforms, ROCK1 and ROCK2, which are
ubiquitously expressed in the human and mouse18. As a serine/threonine kinase, Rho kinase
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phosphorylates residues on many target proteins, including adducin, vimentin, LIM-kinase, and the
myosin-binding subunit of myosin phosphatase (MYPT). ROCK1 and ROCK2 knockout mice are
generally embryonic lethal; less than 10% of C57BL/6 mice survive, dying with open eyes and
omphalocele. The most oft-used inhibitors of Rho kinase are Y-27632 and Fasudil (Fas).
This thesis investigates the role of Rho kinase in AngII-mediated autonomic dysfunction.
The RhoA/Rho-kinase pathway has been demonstrated to play a key role in Ang II signaling and
function in non-neuronal cells, including vascular smooth muscle cells, endothelial cells, and
cardiomyocytes19–22. Selective knockout of a specific RhoA activator from the vascular smooth
muscle cells of mice completely prevents the pressor effect of systemic AngII infusion without
affecting basal blood pressure23. AngII signaling through the AT1R activates RhoA by several
mechanisms, including stimulating RhoGEFs Arhgef123 and p63RhoGEF24 and inhibiting RhoGAP
p190A25. In the context of cardiovascular disease, Rho kinase activation stimulates formation of
the sympatho-excitatory superoxide radical via phosphorylation of p38-MAPK which in turn
activates NADPH oxidase, and Rho kinase decreases nitric oxide synthesis by decreasing the nitric
oxide synthase activity and destabilizing its mRNA. Thus, central Rho kinase activation by AT1R
signaling would be expected to raise sympathetic outflow

Physiological Variability, Autonomic Rhythms, and Pink Noise
All physiological parameters that we measure (e.g., heart rate, arterial pressure, renal blood
flow, renal sympathetic nerve activity) display considerable variability over time. The autonomic
nervous system is an important source of this physiological variability, and changes in autonomic
outflow, either acutely after pharmacological blockade or chronically with the development of
disease, alter the variability of physiological parameters. Much of this thesis is dedicated to the
investigation of physiological variability and the exploration of the autonomic underpinnings
thereof. While measures of physiological variability are prognostic for mortality among patients
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with cardiovascular and renal disease, the clinical utility of such measures is very low despite over
a century of investigation (and about 45 years using digital signal processing techniques).
The autonomic nervous system is not the only source of variability in physiological
parameters, although it is the fastest-acting source of variability. The fact that the autonomic
nervous system acts faster than other systems allows one to appreciate its importance even with
short-term (~5 minutes in the human) recordings of parameters like heart rate or arterial pressure.
This also allows its influence to be examined using frequency analysis, which is a technique by
which a signal occurring in time is decomposed into frequency (see Chapter III for a more
comprehensive introduction). The sympathetic nervous system makes important contributions to
peripheral resistance, arterial pressure, and heart rate variability in the low-frequency (LF) range.
The parasympathetic nervous system affects heart rate variability (and thereby arterial pressure
variability) in both the LF and high-frequency (HF) ranges. The source of LF oscillations in
autonomic rhythms is debated; the two predominant theories are that these rhythms arise either due
to a central oscillator that oscillates in this LF range or due to resonance arising from time delays
in the baroreflex arc. The HF oscillations in heart rate variability arise due to the mechanical effects
of respiration on the circulation, which in create rhythms in autonomic outflow at these frequencies.
The reason that only the parasympathetic nervous system can cause HF oscillations in heart rate is
due to the presence of fast, muscarinic ionotropic receptors at the sinoatrial node, which allow these
HF oscillations in vagal nerve activity to affect heart rate (whereas the slow, adrenergic
metabotropic receptors act as a low-pass filter, eliminating such rhythms).
Underlying these rhythmic contributions of the autonomic nervous system to physiological
parameters are rhythms in efferent traffic along the autonomic nerves themselves. Sympathetic
nerve activity is rhythmic and entrains to the respiratory frequency, which falls in the HF range,
and to the cardiac frequency. Another important sympathetic rhythm occurs in the LF range, giving
rise to arterial pressure oscillations known as Mayer waves as well as sympathetic rhythms in HR.
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One should not introduce short-term physiological variability without talking about pink
noise, which is the other significant source of variability in autonomic frequency ranges. Pink noise
is so named because it falls somewhere between white (Gaussian) and red (Brownian) noise. White
noise is noise with a flat power spectrum (like white light, which contains equal power of all
wavelengths in the visible spectrum); each new value of white noise is completely random and
independent of the previous value. Red noise is simply the integral of white noise; it is noise where
each new value is the sum of a completely random value and the previous value. With many
additions, the previous value component outweighs the contribution of the new random values
(which may be negative or positive, frequently negating one another), and, with slow changes more
common than fast changes, low-frequencies predominate (like red light, the lowest-frequency light
in the visible spectrum). The power spectrum for red noise follows a 1/frequency2 power-law. Pink
noise is just a bit of red and white noise mixed together, resulting in a 1/frequency power spectrum.
Sophisticated techniques can characterize this fractal component of physiological variability 26.
Analyzing physiological signals over the last four years has given me a few insights that I
feel are underappreciated and merit emphasis. First, the mean value of a physiological measure is
more important than any measure of variability. In many manuscripts, the authors dedicate
paragraphs to their discussion of changes in HR variability (HRV) when a change in HR receives
only passing mention. Not only is the mean measure more important, but measures of variability
correlate in some way with the mean measure, and thus using measures of variability in the presence
of mean differences is inherently confounded. Second, time-domain variability affects frequencydomain variability; the total variance in time is equal to the total spectral power in frequency by
Parseval’s theorem. Third, different frequency ranges are not independent of one another (because
of the presence of pink noise, which gives physiological variability its characteristic, inverse powerlaw spectrum). The interdependence of these parameters is important for scientific reporting and
physiological interpretation. Where any frequency-domain parameter is reported, so, too, should
all other frequency-domain indexes, time-domain indexes, and the parameter mean be reported.
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Objectives of the Dissertation
I believe that the autonomic nervous system is important on a patient-by-patient, minuteto-minute basis in both health and disease, and thus, any contributions which advance our
understanding of autonomic outflow, whether by elucidating the molecular mechanisms of
autonomic regulation, validating widely used techniques for autonomic assessment, or developing
new methods to assess autonomic outflow, are important. This thesis is made up of three distinct
contributions to our understanding of autonomic outflow in which I played a key role, and this
conviction is the common thread that ties them together.
Specifically, the objectives set forth in this dissertation are as follows:
1. To assess the functional role of Rho kinase in the autonomic effects of central AngII in
conscious, chronically instrumented rabbits.
2. To investigate the correlation and agreement between measures of heart rate variability
obtained by electrocardiography and pulse rate variability obtained by indwelling arterial
pressure catheters as well as the autonomic basis for each signal.
3. To test the dogma that the sympathetic nervous system does not control renal blood flow except
in disease.
These seemingly disparate objectives all target the overarching goal of quantitatively
evaluating autonomic function as an integrated system and its coupling to circulatory
regulation. Each objective will be presented in the following chapters with each study
containing a brief introduction, detailed methods, results and brief discussion of major findings.
A final discussion will follow, an overview of the major findings and implications of the
dissertation.
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Chapter I: Central Angiotensin-II Increases Blood
Pressure and Sympathetic Outflow via Rho Kinase
Activation in Conscious Rabbits

15

Introduction
Activation of the RAAS and sympatho-excitation are important maladaptive mechanisms
in cardiovascular, renal, and metabolic disease27–30. In these chronic diseases, the RAAS and the
sympathetic nervous system interact in a particularly deleterious, feedforward manner 15,31. The
primary effector peptide of the RAAS, AngII acts via the AngII type 1 receptor
in the brain to raise blood pressure, increase sympathetic outflow, and impair baroreflex
function32,33. Recently, the intracellular mediators of AT1R signaling in both the periphery and the
brain have garnered increasing interest19,34,35. Specifically, signaling in autonomic centers in the
forebrain like the subfornical organ (SFO) and the paraventricular regions of the hypothalamus
(PVH) is particularly important experimental models of AngII-induced hypertension and
cardiovascular disease36–40.
Many studies have shown that the RhoA/Rho kinase pathway is a crucial downstream
effector of AT1R activation by AngII in the heart, endothelium, and vasculature 20,21,23. RhoA/Rho
kinase is particularly important in actin cytoskeleton assembly, calcium sensitization, and nitric
oxide bioavailability41,42. Patients with diseases characterized by RAAS activation and autonomic
dysfunction like hypertension and heart failure have elevated peripheral Rho kinase activity24,43–45.
While logistical issues have prevented assaying central Rho kinase activity in patients,
central Rho kinase activity is elevated in experimental models of hypertension and heart failure44,46–
49

. Moreover, central Rho kinase inhibition has beneficial autonomic effects in experimental models

of cardiovascular disease44,46,48–51. Despite the importance of Rho kinase in peripheral AT1R
signaling and central autonomic regulation, the interaction between the autonomic effects of central
AngII and the Rho kinase pathway has never been directly tested. Therefore, in the present study,
we hypothesized that AngII mediates its central effects by activation of the Rho kinase pathway,
leading to baroreflex dysfunction, increased sympathetic tone, and hypertension.
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Methods
Animals
Experiments were carried out on male New Zealand White rabbits ranging in weight from
3.1 to 4.5 kg (Charles River Laboratories, International, Wilmington, MA). All experiments were
reviewed and approved by the University of Nebraska Medical Center Institutional Animal Care
and Use Committee and carried out in accordance with the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. Rabbits were housed in individual cages
in a temperature-controlled room (23º C) with a 12:12 hour light-dark cycle (lights on at 07:00,
lights off at 19:00). Rabbits were given ad libitum access to reverse-osmosis purified water and
high-fiber rabbit chow (Teklad 2031, Envigo RMS, Indianapolis, IN).

Within-subjects Cohort
To test the hypothesis that Rho kinase activation mediates the hemodynamic and
autonomic effects of central AngII, six rabbits were instrumented with arterial pressure (AP)
radiotelemetry transducers and intracerebroventricular (ICV) cannulae. Each rabbit received ICV
infusions of AngII (40 ng/min; Sigma-Aldrich Corp., St. Louis, MO), AngII plus the Rho kinase
inhibitor Fasudil (Fas, 175 ng/min; GeneDEPOT, Barker, TX), Fas alone, and artificial
cerebrospinal fluid vehicle (Veh) via osmotic minipump in a randomized order. Mean arterial
pressure (MAP) and HR were measured daily, and volume status32, cardiac parasympathetic
tone33, cardiac sympathetic tone, global sympathetic vasomotor tone, and baroreflex function were
assessed on days 10 through 14 of treatment by IV administration of FITC-sinistrin, autonomic
blockers, or vasoactive drugs. This time period (days 10 through 14 of treatment) is referred to as
the late phase of treatment. Between treatment infusions, rabbits received a 7-14 day washout with
a Veh minipump.

Between-subjects Cohort

17
To test the hypothesis that Rho kinase activation mediates the renal sympatho-excitation
caused by central AngII, rabbits were instrumented with radiotelemetry transducers, ICV cannulae,
and renal sympathetic nerve electrodes. Seven days after renal nerve electrode surgery, resting
RSNA and baroreflex control of RSNA were assessed. Not all chronic sympathetic nerve electrode
implantations were successful (Figure 6), and rabbits without RSNA bursts one week after
implantation were excluded from the study. Rabbits were subsequently euthanized and perfused
with paraformaldehyde, and their brains were collected for molecular analysis.

Chronic Instrumentation
Each rabbit was chronically instrumented with an arterial pressure (AP) radiotelemetry and
an ICV cannula connected to an osmotic minipump using sterile surgical technique. Following
induction with an intramuscular bolus of ketamine (35 mg/kg) and xylazine (5.8 mg/kg), rabbits
were intubated, and anesthesia was maintained with 1-2% isoflurane. After a femoral cut down, the
tip of an AP telemetry catheter (model PA-C40, Data Sciences International, New Brighton, MN)
was advanced into the abdominal aorta via the right femoral artery and secured. A scalp incision
was made, the skull was cleared of connective tissue, and an ICV cannula was implanted 3 mm
lateral to bregma. A periscapular incision was made, and a catheter was threaded subcutaneously
from the scalp to the periscapular subcutaneous pocket. The cranial end of the catheter was
connected to the ICV cannula, and the caudal end was connected to a vehicle-filled osmotic
minipump (Alzet 2ML2, DURECT Corporation, Cupertino, CA). On the day of surgery, rabbits
received pre-surgical enrofloxacin (22.7 mg subcutaneous, Bayer HealthCare LLC, Shawnee
Mission, KS) and buprenorphine for pain control upon emergence from anesthesia. Rabbits
received a three-day post-operative course of enrofloxacin and carprofen (4 mg/kg subcutaneous,
Zoetis, Lincoln, NE) respectively. Each rabbit was allowed to recover for at least ten days, during
which time the rabbit was acclimated to the procedure room and trained to rest calmly in a Plexiglas
box. Rabbits in the between-subjects cohort underwent a subsequent surgery in which a bipolar
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electrode was implanted on the left renal nerve. The left kidney was approached retroperitoneally
via a flank incision, the largest renal nerve bundle was carefully dissected, and two platinum
electrodes were wrapped around the dissected nerve section and fixed using Kwik-Sil adhesive
(World Precision Instruments, Inc., Sarasota, FL). A ground loop electrode was secured to nearby
tissue with 6-0 Prolene. Each electrode was electrically coupled to a Teflon-coated stainless steel
wire, which was fixed to the renal artery with 6-0 Prolene, and all three leads were exteriorized via
a common Silastic tube. The ICV vehicle infusion osmotic minipump was replaced with a treatment
osmotic minipump, as described below, during the same surgery. Rabbits were given the same
perioperative antibiotic regimen as above, but the analgesic regimen was supplemented with a 72hour fentanyl patch (25 mcg/hr transdermal). Rabbits were allowed to recover seven days from
RSNA surgery before experiments were begun.

Replacement of Osmotic Minipumps
Osmotic minipumps were replaced using sterile technique under general and local
anesthesia with AP and heart rate (HR) monitoring. Rabbits were anesthetized with an
intramuscular bolus of ketamine (17.5 mg/kg) and xylazine (2.9 mg/kg) and a local periscapular
infiltration of bupivacaine (0.25 mg). An incision was made into the periscapular subcutaneous
pocket containing the osmotic minipump to be replaced, and the pump was removed and the
catheter connecting it to the ICV cannula was cut. A new osmotic minipump was connected to the
catheter and implanted. The incision was closed with interrupted, external Prolene sutures. The
content of the osmotic minipump was aspirated, and the aspirated volumes were always within 2
standard deviations of the manufacturer tolerances for pump volume and pump rate. When
treatment pumps were placed, the function of the catheter and ICV cannula was first tested by
giving a 100 nmol AngII bolus, which robustly raises MAP when given ICV but has no effect on
if given subcutaneously (e.g., if the catheter is disconnected from the ICV cannula). Rabbits
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received the same antibiotic regimen as for instrumentation and a one-time post-operative dose of
buprenorphine (0.02 mg/kg subcutaneously) for pain control.

Dose-Finding Study
Three rabbits were used in a pilot study to identify doses of Angiotensin-II which
raised blood pressure when administered ICV. Four ICV doses (10 ng/min, 20 ng/min, 30 ng/min,
and 40 ng/min) were attempted, with only the highest showing a pressor effect. Three ICV doses
(87.5 ng/min, 175 ng/min, and 350 ng/min) of Fas were co-infused with AngII. The two rabbits
who initially received the lowest dose of Fas did not show any attenuation of the pressor effect of
AngII. The rabbit who received the highest dose suffered acute neurological symptoms
approximately 18 hours after implantation of the minipump and died quickly thereafter. It is unclear
if this was related to central Rho kinase inhibition or an off-target mechanism. The 175 ng/min
dose of Fas blocked the pressor effect of central AngII, but, clearly, the therapeutic window for
central Fas to block the pressor effect of central AngII in rabbits is relatively narrow. The results
for the two rabbits who completed the dose-finding study were used for power analysis.

Resting Recordings from Within-Subjects Study
The rabbits rested in a Plexiglas box in a dimly lit procedure room for at least 30 minutes
at approximately the same time each morning. Pulsatile AP was digitized at a sampling frequency
of 1 kHz via a 16-channel PowerLab system (ADInstruments, Inc., Colorado Springs, CO). Heart
rate was derived from the pulse rate of the AP signal.

Pharmacological Assessment of Autonomic Tone
Intravenous (IV) administration of autonomic blockers in the afternoon of days 11 through
13 was used to assess the effects of ICV treatments on autonomic tone. After local infiltration with
bupivacaine, an IV catheter was inserted into a marginal ear vein to allow IV administration of
cardiac autonomic blockers. Each rabbit was allowed to rest for ten minutes after the placement of
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the IV catheter, at which point a 1 mL bolus of saline was given and recording of pulsatile arterial
pressure was initiated. Fifteen minutes later, atropine methyl bromide (0.2 mg/kg bolus; SigmaAldrich Corp., St. Louis, MO), metoprolol bitartrate (1 mg/kg bolus; Sigma-Aldrich Corp., St.
Louis, MO), or hexamethonium bromide (3 mg/kg/min infusion for ten minutes; Sigma-Aldrich
Corp., St. Louis, MO) was administered IV. Atropine, a muscarinic antagonist, blocks the effects
of vagal control of sinoatrial node rhythmicity, and thus the increase in HR after atropine is a
surrogate for resting cardiac parasympathetic tone. Metoprolol, a beta1-adrenergic antagonist,
blocks the effects of sympathetic control of sinoatrial node rhythmicity, and thus the decrease in
HR after metoprolol administration is a surrogate for resting cardiac sympathetic tone.
Hexamethonium, a ganglionic blocker, causes hypotension mainly by blocking sympathetic
vasoconstrictor tone, and thus the maximal decrease in AP during the course of the hexamethonium
infusion is a surrogate for global resting sympathetic vasomotor tone.

Assessment of Baroreflex Control of Heart Rate
On the afternoon of day 14, baroreflex control of HR was assessed by infusion of
vasoactive drugs. After IV access was obtained as above, an IV infusion of sodium nitroprusside
(100 µg/kg/min) was initiated and AP was driven down until HR reached a plateau. After the rabbit
recovered completely, an infusion of phenylephrine (40 µg/kg/min) was initiated, and AP was
driven up until HR reached a plateau. The HR and systolic blood pressure (SBP) for each beat were
paired, and these pairs were then separated based on SBP into 2 mmHg wide bins. The median SBP
and HR for each bin were fitted to a five-parameter logistic equation52.

Volume Status Experiment
Four of the six rabbits underwent a volume status study on day 10 of ICV treatment
using a previously described protocol in order to assess effects of the ICV treatment on volume
regulation53. This was undertaken to because of the widely touted importance of renal sympathetic
control of volume status in hypertension. This was a technique that we had not perfected when the
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first two rabbits were enrolled, hence their exclusion. Briefly, the marginal ear vein and central ear
artery of the conscious rabbit were catheterized after local lidocaine infiltration. A bolus of FITCsinistrin (Fresenius Kabi, Linz, Austria) was given IV and quickly flushed. Blood samples (3 mL)
from the arterial catheter were collected at 3, 7, 10, 15, 45, 75 and 105 minutes after the FITCsinistrin bolus. The plasma fluorescence was measured and compared to a standard curve in order
to derive the FITC-sinistrin plasma concentration. The FITC-sinistrin plasma concentration was
fitted to a two-exponential decay equation, and the physiological parameters of the fitted open twocompartment pharmacokinetic model were derived. Specifically, glomerular filtration rate (GFR),
the volumes of the high- and low-perfusion compartments (Vhigh-perfusion and Vlow-perfusion,
respectively), and the first-order kinetic constants between the compartments khigh→low and klow→high
and out of the system kelim (i.e. GFR/Vhigh-perfusion) are reported. The sum of the high- and lowperfusion compartments equals the extracellular fluid volume (ECFV).

Recording of RSNA
RSNA was differentially pre-amplified 10,000-fold, band-pass filtered from 100 to 1000
Hz (Grass P55, Natus Medical Inc., Warwick, RI), digitized at 1 kHz, rectified, and integrated with
a 20-ms time constant. Resting RSNA was quantified as a percent of the nasopharyngeal reflex,
burst frequency, and burst incidence. The nasopharyngeal reflex was elicited by drawing thick
cigarette smoke into a 60-mL syringe and emptying the syringe into the face of the rabbit over 10
seconds. At the end of the experiment, the electrical zero (i.e. noise) was determined by
administering a 30 mg/kg IV bolus of hexamethonium, which abolished RSNA. The resting
integrated nerve activity minus the electrical zero was expressed as a percent of the maximal fivesecond integrated RSNA during elicitation of the nasopharyngeal reflex minus the electrical zero
(i.e. [resting activity – electrical zero]/[nasopharyngeal maximum – electrical zero]x100%). Burst
frequency was determined by manually setting a burst threshold above the noise floor of an artifactfree section of resting activity with a retrigger delay of 100 msec and expressed as bursts/min. Burst
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incidence, the number of bursts per 100 heart beats, was determined by normalizing the burst
frequency to the HR. Baroreflex control of RSNA was assessed just as performed as described
above, except the rate of phenylephrine infusion was decreased from 40 µg/kg/min to 10 µg/kg/min.
Beat-averaged integrated RSNA was paired with the preceding DBP, and these pairs were then
separated based on DBP into 2 mmHg wide bins. The median DBP and integrated RSNA for each
bin were fitted to a five-parameter logistic equation, but because baroreflex control of RSNA in the
rabbit shows hypo- and hypertensive reversal54, the lower plateau and the range of the logistic curve
were fixed to match the DBP bins with the lowest and highest RSNA, respectively. Frequencydomain analysis was performed on RSNA. In brief, 5-minute artifact-free sections of data were
linearly reinterpolated at 5.12 Hz, and the modified periodogram was computed via the Welch
method using 50% overlapping, Hamming-tapered 60-second windows. VLF was considered 00.20 Hz, LF was considered 0.20 Hz to 0.45 Hz, and HF was considered 0.76 to 1.5 Hz, and the
power in these frequencies is expressed as a percentage of the total power from 0-1.5 Hz. We
hypothesized that greater sympathorespiratory coupling would result in elevated RSNA HF power
in AngII-infused rabbits.

Assessment of Rho Kinase Activity
To validate that central AngII activates Rho kinase and that this activation is inhibited by
Fasudil, Rho kinase activity was assessed using a LiCor Odyssey scanner to perform quantitative
immunofluorescence55 on sagittal brain slices with antibodies raised against the 696-threonine
phosphorylated form of the Rho kinase target myosin phosphatase targeting protein (p-MYPT).
Rabbits were anti-coagulated with heparin (1000 international unit IV bolus), euthanized
with 3 mL Fatal-Plus (Vortech Pharmaceuticals, Dearborn Michigan) IV bolus, and an intracardiac
perfusion was performed with Tris-buffered saline (TBS) followed by 4% paraformaldehyde. The
tissue was quickly removed and post-fixed for 36 hours in 4% paraformaldehyde and dehydrated
in 3% sucrose prepared with TBS at 4°C. Next, a midline sagittal cut was made and one half of the
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brain was blocked on an aluminum plate in Tissue Tek OCT Compound (Sakura Finetek, Torrance,
CA) medium and stored at – 80°C until further processing. On the day of processing, brain tissue
was acclimated to - 20°C and the tissue was sliced into 150 µm sections starting at the midline and
placed in TBS.
Tissue slices were placed in TBS-based blocking buffer for 1 hour at room temperature
with gentle shaking (LiCor, Lincoln, NE). Following this, the slices were exposed to a solution of
1:1000 p-MYPT mouse primary antibodies (sc-377531, Santa Cruz Biotechnology, Santa Cruz,
CA) overnight at 4 °C with gentle shaking. The following morning, slices were rinsed with
moderate shaking 4x for 15 minutes in 0.1% TBS-T. Slices were then exposed to a 1:10,000 dilution
of donkey anti-mouse secondary antibody (925-68022, LiCor Bioscienes, Lincoln, NE) while
protected from light with gentle shaking at room temperature. After incubation the tissues were
rinsed with moderating shaking 4x for 15 minutes at room temperature, while protected from light.
Slices were then placed into TBS until mounted. Tissues were removed from the TBS and mounted
using a Versatool Kit (Elegant Instruments, Omaha, NE), placed on a glass slide, briefly rinsed in
water and allowed to dry at room temperature protected from light for an allowed to completely
dry before scanning.
All brains were scanned together at 42 µm resolution using a LiCor Odyssey Scanner. The
resulting fluorescence image was then exported to MATLAB for image processing. The
fluorescence intensity histogram was clearly bimodal, with the low-intensity background pixels
composing one peak and the high-intensity brain tissue pixels composing another peak. The
fluorescence intensity histogram was used to manually identify the maximum background intensity
for the entire fluorescent image by selecting an intensity value that was between both peaks. Then,
each brain slice was coarsely traced, and that region was then thresholded to exclude pixels whose
intensity was below the maximum background intensity (indicating there was no brain, e.g., pixels
in the third ventricle). This brain mask was then used to quantify the mean intensity (after
subtracting the maximum background intensity) for each slice as well as for the quantification of
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the mean p-MYPT fluorescence intensity in the SFO and PVH of each brain. Within each brain
mask, the SFO was carefully traced, and the difference between the mean fluorescence intensity
the maximum background intensity was used as the Rho kinase activity level. In a saggital slice, it
is impossible to know the exact borders of the paraventricular hypothalamic nucleus (PVN), so we
have adopted the nomenclature PVH in acquiescence of this fact. Uniformly sized and oriented
boxes (see Figure 9) were placed in the PVH, and the mean p-MYPT fluorescence intensity above
the background was used as an assessment of Rho kinase activity in the PVH.

Power Analysis and Sample Size Justification
The within-subjects cohort was powered to detect an AngII x Fas interaction on MAP via
two-way ANOVA (Figure 1). Data from the dose-finding study were used for power analysis. The
mean and standard deviation of MAP for each treatment were calculated and used to calculate the
AngII x Fas and within-treatment sum-square error using a simple between-subjects two-way
ANOVA approach, obviating known difficulties with multi-factor RM ANOVA power analysis56.
This yields a more conservative estimate of sample size as the within-subjects design increases
power. Since we did not have data for Fas alone infusion and had previously observed no effect on
MAP from ICV Fas infusion (albeit a different dose) in healthy rabbits46, the Veh mean and
standard deviation were used for power analysis. The AngII x Fas and within-treatment sum of
squares were used to calculate the effect size η2, and GPower was used to compute the required
sample size for β > 0.80. This showed that we needed 5 rabbits per treatment; we enrolled 6 rabbits
due to the likelihood of instrumentation failure over the course of such a long study. All rabbits
completed all four treatments.
The between-subjects cohort was powered to detect an AngII x Fas interaction on resting
RSNA via two-way ANOVA using data from the literature (Figure 6). A study of 15 normal rabbits
showed that RSNA when normalized to the nasopharyngeal reflex was 7.0% with a standard
deviation of 4.6%57. Another previous study showed that a seven-day infusion of a non-pressor
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dose of ICV AngII caused a 2.6-fold increase in resting RSNA normalized to the nasopharyngeal
reflex with a similar increase in the standard deviation of resting RSNA, thus 18.4% was estimated
as the mean and 12.0% the standard deviation for AngII-infused rabbits58. We assumed that Fas
alone would not affect RSNA and that coadministration of Fas would completely block the AngIImediated renal sympatho-excitation, mirroring what we had observed with global sympathetic
vasomotor tone in the within-subjects study (i.e. μFas = μAngII+Fas = μVeh and σFas = σAngII+Fas = σVeh).
This was used to compute an effect size η2, and GPower was used to compute the required sample
size for β > 0.80.

Statistical Analysis
Individual data are shown via dot plots with each dot representing one rabbit, and group
data are displayed as group mean ± SEM. Statistical testing on endpoints from the within-subjects
study was performed using two-way or three-way repeated measure (RM) analysis of variance
(ANOVA) with α = 0.05. Statistical testing on endpoints from the between-subjects study was
performed using two-way ANOVA with α = 0.05. The P values for the AngII, Fas, and AngII x
Fas terms from the ANOVA are reported throughout the manuscript. Crucial to the central
hypothesis of this manuscript, PAngII x Fas < α indicates that the response to AngII is significantly
modified by Fas, i.e. that there is a non-additive interaction between AngII and Fas. This allows
for statistical testing of the hypothesis that the effects of AngII are mediated by the Rho kinase
pathway. In the absence of a significant interaction (i.e. PAngII x Fas >> α), PAngII < α indicates that
AngII significantly affects the endpoint independent of Fas. This would be the expected result for
a Rho kinase-independent effect of AngII. If the ANOVA reached statistical significance, it was
followed by Bonferroni-corrected, paired t-tests of Veh versus AngII and AngII versus AngII+Fas
(α = 0.025). These t-tests were chosen as they most closely relate to the central hypothesis of the
study while other t-tests (e.g., Veh vs. Fas) were foregone in order to decrease the effect of
corrections for multiple comparisons on power.
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Figure 1 – Power Analysis and Flow Chart for the Within-Subjects Cohort.
(A) Power analysis for effect of ICV treatment on MAP observed in dose-finding study. (B)
Each rabbit received all four ICV treatmments in random order.
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Figure 2 – Baseline Hemodynamics from the Within-subjects Cohort.
(A) Within-subjects study design illustrating basic experimental paradigm. (B) Average MAP
over the course of each ICV treatment infusion and (C) the average MAP for each rabbit over
days 10 through 14 of each ICV treatment. (D) Average HR over the course of each ICV
treatment infusion and (E) the average HR for each rabbit over days 10 through 14 of each
treatment infusion. *, P < 0.025; **, P < 0.01
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Results
Resting Hemodynamics
We set out to evaluate the role of the Rho kinase pathway in the effect of AngII on basal
hemodynamics by measuring MAP and HR daily over the course of ICV treatments. Power analysis
and treatment order for this cohort can be found in Figure 1 while the experiment paradigm is
shown in Figure 2A. Compared to Veh treatment, ICV infusion of AngII significantly increased
MAP in all rabbits (Figure 2B and C), and this increase in MAP was abolished by co-administration
of Fas. The statistically significant interaction between AngII and Fas indicates that ICV AngIImediated increases MAP are dependent on Rho kinase activation. Conversely, none of the
treatments had a significant effect on HR during the entire course of the infusion (Figure 2D) or in
the late phase of infusion (Figure 2E).
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Figure 3 – Autonomic Blockade Experiments.
(A) Cardiac parasympathetic tone assessed by the HR response to atropine. (B) Cardiac
sympathetic tone assessed by the HR response to metoprolol. (C) Global sympathetic vasomotor
tone assessed by the MAP response to hexamethonium. *, P < 0.025; **, P < 0.01

Table 1 – Heart rate from atropine experiments
Veh

Fas

AngII

AngII+Fas

PAngII x Veh

PAngII

PFas

HR before atropine (bpm)

196 ± 10

205 ± 9

199 ± 5

197 ± 14

0.55

0.63

0.67

HR after atropine (bpm)

255 ± 17

259 ± 13

260 ± 10

259 ± 16

0.83

0.65

0.83

Table 2 – Heart rate from metoprolol experiments
Veh

Fas

AngII

AngII+Fas

PAngII x Veh

PAngII

PFas

HR before metoprolol
(bpm)

204 ± 15

193 ± 13

205 ± 7

192 ± 15

0.88

0.94

0.06

HR after metoprolol
(bpm)

203 ± 14

193 ± 12

185 ± 3

191 ± 14

0.41

0.29

0.66

Table 3 – Mean arterial pressure from hexamethonium experiments
Veh

Fas

AngII

AngII+Fas

PAngII x Veh

PAngII

PFas

MAP before
hexamethonium (mm Hg)

82 ± 2

79 ± 2

101 ± 4

78 ± 2

< 0.05

< 0.05

< 0.01

MAP after
hexamethonium (mm Hg)

53 ± 2

52 ± 2

55 ± 5

50 ± 2

0.56

0.96

0.23
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Pharmacological Assessment of Autonomic Balance
Cardiac parasympathetic tone was assessed by the HR response to atropine. This was not
significantly affected by any ICV treatment (Figure 3A, Table 1). Cardiac sympathetic tone
assessed by the HR response to metoprolol was significantly increased by ICV infusion of AngII,
and this cardiac sympatho-excitation was blocked by Fas co-administration (Figure 3B, Table 2).
The statistically significant interaction between AngII and Fas indicates that the AngII-mediated
cardiac sympatho-excitation depends on Rho kinase activation.
Global sympathetic vasomotor tone assessed by the MAP response to hexamethonium was
significantly elevated by ICV infusion of AngII, and again co-administration of Fas blocked this
elevation despite Fas alone having little effect (Figure 3C, Table 3). This interaction between AngII
and Fas indicates that AngII elevates sympathetic vasomotor tone by Rho kinase activation.
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Figure 4 – Baroreflex Control of HR.
(A) Composite curves showing baroreflex control of HR for each treatment as well as the upper and lower plateaus of the 5parameter logistic curves. (B) Composite baroreflex gain curves showing HR baroreflex sensitivity for each treatment as
well as the average maximal gain for each treatment. Gmax, maximal gain of 5-parameter logistic curve

Table 4 – Additional parameters from logistic equations of baroreflex control of HR
Veh

Fas

AngII

AngII+Fas

PAngII x Veh

PAngII

PFas

P2, Range
(bpm)

268 ± 19

245 ± 17

267 ± 37

247 ± 23

0.27

0.54

0.63

P3, Lower
Curvature

-0.06 ± 0.01

-0.11 ± 0.02

-0.10 ± 0.02

-0.14 ± 0.06

0.53

0.20

0.34

P5, Upper
Curvature

-0.10 ± 0.04

-0.05 ± 0.01

-0.03 ± 0.01

-0.06 ± 0.01

0.13

0.10

0.71

P4, BP50
(mmHg)

97 ± 3

100 ± 4

119 ± 7

100 ± 5

0.09

< 0.05

0.07

Asymmetry

0.02 ± 0.51

0.74 ± 0.07

1.18 ± 0.27

0.61 ± 0.17

0.06

0.19

0.54

Curvature

0.05 ± 0.01

0.07 ± 0.01

0.04 ± 0.01

0.08 ± 0.02

0.10

0.97

0.09

P2, the range parameter; P3, the lower curvature parameter; P5, the upper curvature parameter; P4, the
systolic blood pressure at which half of the range in heart rate was attained from the fitted 5-parameter
logistic function, n = 6 for each treatment.
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Assessment of baroreflex function with vasoactive drugs showed that ICV AngII caused a
right-shift of the cardiac baroreflex curve in these rabbits without significantly affecting any other
indexes of cardiac baroreflex function like gain or range (Figure 4 and Table 4). Fas decreased the
lower HR plateau independent of AngII, consistent with Fas-mediated augmentation of maximal
vagal outflow.
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Figure 5 –Assessment of Volume Status by FITC-Sinistrin Distribution.
(A) Extracellular fluid volume. (B) Volume of the Low-Perfusion Compartment. (C) Volume of the High-Perfusion
Compartment, n = 4 per treatment.

Table 5 – Additional Parameters from Two-compartment FITC-Sinistrin Pharmacokinetics
Veh

Fas

AngII

AngII+Fas

PAngII x Veh

PAngII

PFas

Glomerular
Filtration Rate
(mL/min)

11.2 ± 0.6

11.2 ± 1.7

12.1 ± 1.2

10.0 ± 1.0

0.50

0.93

0.13

kelim (min-1)

0.042 ±
0.002

0.073 ±
0.011

0.055 ±
0.012

0.060 ±
0.010

0.18

0.97

0.23

khigh→low (min-1)

0.079 ±
0.008

0.143 ±
0.033

0.138 ±
0.057

0.160 ±
0.039

0.09

<
0.05

0.07

klow→high (min-1)

0.057 ±
0.004

0.076 ±
0.016

0.074 ±
0.017

0.075 ± 0.17

0.53

0.36

0.60

kelim, plasma elimination kinetic constant; khigh→low, kinetic constant for flux from high-perfusion to
low-perfusion compartment, klow→high, kinetic constant for flux from low-perfusion to lowperfusion compartment, n = 4 for each treatment
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Assessments of volume homeostasis showed that, despite increases in MAP, extracellular
fluid volume was not decreased in rabbits receiving ICV AngII, nor did AngII affect other twocompartment model parameters (Figure 5 and Table 5).

Figure 6 – Power Analysis and Flow Chart for Between-subjects Cohort.
Study Design and Flow Chart for the Between-Subjects Cohort. (A) Power analysis for baseline
RSNA based on literature values. (B) Each rabbit received one ICV treatment, rabbits without
RSNA bursts after a one-week recovery from RSNA surgery were excluded from analysis.
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Figure 7 – Resting RSNA from Between-subjects Cohort.
(A) Between-subjects cohort study design illustrating basic experimental paradigm. (B) Representative tracings of
pulsatile arterial pressure, raw RSNA, and integrated RSNA for one rabbit receiving each ICV treatment. (C) RSNA
normalized to the nasopharyngeal reflex. (D) Baseline RSNA quantified as burst frequency. (E) Baseline RSNA
quantified as burst incidence. **, P < 0.01

Table 6 – Resting Hemodynamics for Between-subjects Study
Veh

Fas

AngII

AngII+Fas

PAngII x Veh

PAngII

PFas

MAP (mm Hg)

75 ± 3

78 ± 2

91 ± 4*

74 ± 3†

< 0.01

0.05

0.08

HR (bpm)

203 ± 5

205 ± 6

197 ± 10

205 ± 12

0.70

0.71

0.54

Resting mean arterial pressure (MAP) and heart rate (HR) 7 days after RSNA electrode
implantation. *, P < 0.025 vs AngII; †, P < 0.025 vs. AngII+Fas, n = 4 for each treatment.
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Table 7 – RSNA Spectral Distribution
Veh

Fas

AngII

AngII+Fas

PAngII x Veh

PAngII

PFas

VLF (% total)

14 ± 3

11 ± 6

20 ± 5

16 ± 3

0.26

0.35

0.41

LF (% total)

22 ± 5

27 ± 6

19 ± 4

18 ± 5

0.11

0.31

0.32

HF (% total)

33 ± 5

32 ± 7

45 ± 9

38 ±7

0.81

0.10

0.63

RSNA spectral distribution 7 days after RSNA electrode implantation. n = 4 for each treatment.
VLF, very low-frequency power (0-0.20 Hz); LF, low-frequency (0.20-0.46 Hz); HF = highfrequency (0.76-1.5 Hz); % total, percentage of power from 0-1.5 Hz

Resting RSNA
We set out to directly measure RSNA in conscious rabbits using. The power analysis and
flow diagram for this cohort is shown in Figure 6, and the experimental paradigm is shown in
Figure 7. Resting hemodynamics are shown in Table 6; notably, AngII-treated rabbits in this cohort
were hypertensive while HR did not significantly differ between treatment groups.
Rabbits receiving ICV AngII had significantly increased baseline RSNA when quantified
as a percent of the nasopharyngeal reflex (Figure 7B and C) and tended to exhibit increased RSNA
burst frequency and burst incidence (Figure 7D and E). Again, Fas alone had little effect, and the
statistically significant interaction between AngII and Fas with regard to normalized RSNA and
RSNA burst incidence indicates that AngII-mediated renal sympatho-excitation depends on Rho
kinase activation. Despite this difference in burst frequency, the spectral distribution of RSNA was
not significantly affected by any ICV treatment although there was a trend for AngII treatment to
increase RSNA HF power (Table 7).
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Figure 8 –Baroreflex Control of RSNA
(A) Composite RSNA baroreflex curves normalized to baseline RSNA. (B) Composite RSNA baroreflex gain curves
normalized to baseline RSNA. (C) Composite RSNA baroreflex curves normalized to the nasopharyngeal reflex. (D)
Composite RSNA baroreflex gain curves normalized to the nasopharyngeal reflex.

Table 8 – Additional parameters from logistic equations of baroreflex control of RSNA
Veh

Fas

AngII

AngII+Fas

PAngII x Veh

PAngII

PFas

P2, Range
(%baseline)

479 ± 72

447 ± 93

132 ± 27*

533 ± 111†

< 0.05

< 0.05

0.14

P2, Range (%max)

58.3 ± 4.1

48.0 ± 7.0

43.5 ± 9.5

53.7 ± 16.4

0.34

1.00

0.67

P3, Lower Curvature

-0.35 ± 0.20

-0.56 ± 0.14

-0.15 ± 0.08

-0.56 ± 0.11

0.33

0.09

0.34

P5, Upper Curvature

-0.40 ± 0.23

-0.43 ± 0.23

-0.34 ± 0.17

-0.21 ± 0.08

0.69

0.79

0.46

P4, BP50 (mmHg)

56.4 ± 2.6

61.5 ± 3.2

77.6 ± 5.3*

58.7 ± 1.5†

< 0.05

0.05

< 0.05

Asymmetry

0.24 ± 0.46

0.50 ± 0.58

-0.70 ± 0.88

1.08 ± 0.31

0.22

0.11

0.77

Curvature

0.30 ± 0.06

0.34 ± 0.10

0.11 ± 0.08

0.29 ± 0.11

0.45

0.22

0.20

P2, the range parameter; P3, the lower curvature parameter; P5, the upper curvature parameter; P4, the systolic
blood pressure at which half of the range in RSNA was attained from the fitted 5-parameter logistic function.
*, P < 0.025 vs. Veh, †, P < 0.025 vs. AngII.
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Baroreflex Control of Renal Sympathetic Nerve Activity
ICV AngII impaired baroreflex control of RSNA compared to Veh treatment, and Fas coadministration prevented this baroreflex dysfunction (Figure 8 and Table 8). When RSNA was
expressed relative to basal RSNA, rabbits receiving AngII showed decreased RSNA baroreflex
range, with the upper plateau significantly lower (P < 0.025 vs. Veh) and the lower plateau
significantly higher (P < 0.025 vs. Veh). These effects depended on Rho kinase activation (PAngII x
Fas

< 0.05). Similarly, AngII treatment lowered baroreflex gain when expressed as a percentage of

basal RSNA (P < 0.025 vs. Veh) only in the absence of Fas coadministration.
We also analyzed baroreflex curves with RSNA normalized to the nasopharyngeal reflex
to account for the aforementioned differences in baseline RSNA (Figure 8C and D). When RSNA
was normalized in this manner, the gain and the range of the RSNA baroreflex curves tended to be
decreased by AngII infusion, but these trends did not reach statistical significance, indicating that
these effects are at least partially related to the differences in basal RSNA. Even after normalization
to the nasopharyngeal reflex, the lower plateau was significantly higher in AngII-infused rabbits
compared to the Veh group (P < 0.025), and this increase depended on Rho kinase activation (PAngII
x Fas

< 0.01). Thus, central AngII acts via Rho kinase activation to cause deficits in the capacity for

baroreflex-induced sympatho-inhibition regardless of how RSNA was normalized.
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Figure 9 – Assessment of Rho Kinase Activity
(A) Representative saggital brain slices stained with antibodies for the Rho kinase target p-MYPT from rabbits infused
with each ICV treatment. (B) Mean SFO p-MYPT fluorescence. (C) Mean PVH p-MYPT fluorescence. (D) Mean
whole-slice p-MYPT fluorescence.
d, dorsal direction; v, ventral direction; r, rostral direction; c, caudal direction; *, P < 0.025.
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Assessment of Rho Kinase Activity
Rho kinase phosphorylates MYPT in the brain59, and this phosphorylation was used as a
marker for Rho kinase activity. AngII treatment increased Rho kinase activity in the SFO, PVH, as
well as the entire slice (Figure 9). Interestingly, in the SFO, AngII treatment increased Rho kinase
in a Fas-independent manner, and Fas decreased Rho kinase activity in an AngII-independent
manner, whereas in the PVH and diffusely, AngII and Fas showed a statistically significant
interaction.

Discussion
In the present study we show that central infusion of AngII increases blood pressure,
elevates sympathetic outflow, and blunts baroreflex function by downstream activation of Rho
kinase. This study builds upon a previous study from our laboratory performed in the rabbit pacing
model of chronic heart failure which showed that central infusion of Fas improved baroreflex
function and cardiac autonomic balance in the setting of heart failure46. These data are also
consistent with other studies in hypertensive rat models which have described central activation of
Rho kinase and shown benefits from central Rho kinase inhibition48–51. Ito et al. showed that
transfection of the nucleus tractus solitarius (NTS) of both spontaneously hypertensive and WistarKyoto rats with a dominant-negative Rho kinase results in decreases in MAP, HR, and urinary
norepinephrine excretion48. These effects were greater in the spontaneously hypertensive rats,
which also had greater Rho kinase activity in the NTS compared to Wistar-Kyoto control rats. Our
study also corroborates one of these studies, which found that subchronic central administration of
the Rho kinase inhibitor Y27632 prevented the pressor effect of central AngII in Sprague-Dawley
rats51. This rat study did not include rats receiving the Rho kinase inhibitor alone and thus was
unable to address the central hypothesis of the current study, nor were direct measurements of
sympathetic nerve activity or baroreflex function performed.
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Baroreflex function, sympathetic outflow, and AP interact in complex ways which merit
further discussion. Studies of baroreceptor unloading and stimulation implicate the baroreflex as
an important controller of chronic sympathetic outflow and arterial pressure60–66. This gives weight
to the possibility that Rho kinase activation mediates sympathetic baroreflex dysfunction which
underlies the sympatho-excitation and hypertension caused by central AngII. In particular, elevated
RSNA is crucial to the development of hypertension because of its ability to impair the powerful
homeostatic mechanism of pressure-natriuresis67–69.

In the within-subjects cohort, neither

extracellular fluid volume nor the high-perfusion compartment volume, which is a surrogate for
intravascular blood volume, were decreased by AngII treatment despite a 19 mmHg increase in AP,
implicating a deficit in pressure-natriuresis with central AngII. This departure from expected
pressure-mediated volume regulation corroborates the idea that elevated RSNA facilitates chronic
elevations in AP during central AngII.
Because of the inherent difficulties in the normalization of RSNA, it is unclear whether the
reported sympathetic baroreflex dysfunction in AngII-treated rabbits leads to elevated RSNA or if
it is the increased RSNA which causes the sympathetic baroreflex to appear perturbed. Clearly,
normalizing the RSNA baroreflex by the nasopharyngeal reflex instead of the baseline RSNA
greatly attenuates the AngII-mediated decrease in sympathetic baroreflex sensitivity and range. But
any further interpretation is prone to a classic chicken-and-egg dilemma as it is just as reasonable
that the AngII-mediated baroreflex dysfunction underlies the observed increases in RSNA as it is
that the AngII-mediated increase in baseline RSNA results in apparent baroreflex dysfunction.
Regardless of how RSNA is quantified, AngII causes a deficit in the maximal pressor-mediated
sympathoinhibition, perhaps indicating that baroreflex dysfunction is the primary disturbance. Of
course, elevations in AP per se affect baroreflex function70,71, further complicating the process of
parsing cause from effect in this truly integrative system.
The activity of Rho kinase in the brains of these rabbits showed interesting differential
patterns. In the SFO, which is a primary sensor and essential mediator of the effects of central and
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peripheral AngII34,72, AngII and Fas significantly affected Rho kinase activity independently, with
no evidence for interaction (PAngII x Fas = 0.46). Conversely, in the PVH, which is an important
preautonomic integration center, and in the whole saggital slice, AngII and Fas interacted in their
effect on Rho kinase activity. The additive nature of the effects of AngII and Fas on Rho kinase
activity in the SFO may indicate that both are acting at this site, with AngII activating RhoA via
AT1R signaling while Fas directly inhibits Rho kinase. In the absence of Fas, AngII increases Rho
kinase activity and drives downstream activation of the PVH and global sympatho-excitation37;
when both AngII and Fas are present, Rho kinase activity in the SFO is relatively normal and these
untoward downstream effects are blocked.
While solid evidence indicates that central AngII stimulates Rho kinase via AT1R
activation51, the intermediaries between AT1R and RhoA/Rho kinase in the brain remain to be
elucidated. In the periphery, AT1R signaling stimulates the RhoGEFs Arhgef1 23 and
p63RhoGEF24, which activate RhoA/Rho kinase, and inhibits the RhoGAP p190A25 which, in turn,
inhibits RhoA/Rho kinase. It is likely that these same mediators are important in the transduction
between AT1R and RhoA in the brain, but other factors may play an important role and this area
merits further study.
The downstream molecular mechanisms by which Rho kinase mediates its effects are likely
multiple. Rho kinase is a crucial part of feedforward AngII-mediated oxidative signaling in the
endothelium and may play a similar role in sympatho-excitatory superoxide signaling in the
preautonomic centers of the brain21,36. Closely intertwined is the effect of Rho kinase to decrease
the production of sympatho-inhibitory nitric oxide, which rapidly reacts with superoxide73. These
free radicals affect neuronal excitability by altering K + and Ca2+ currents34,74. Additionally, Rho
kinase is known to play a fundamental role in neurotransmitter release and dendritic spine
formation48, and thus Rho kinase inhibition might prevent the release of sympatho-excitatory
neurotransmitters and impair neuroplastic conversion to a sympatho-excitatory phenotype.
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The two Rho kinase isoforms (ROCK1 and ROCK2) share approximately 90% homology
in their kinase domains but despite this structural similarity, they are differentially distributed and
perform distinct functions75. Of note, ROCK1 in the hypothalamus has been shown to play an
important role in metabolic regulation, which is closely related to sympathetic outflow76. ROCK2
is more highly expressed in the brain, and induction of heart failure in rabbits by rapid ventricular
pacing increases ROCK2 levels in the rostral ventrolateral medulla, an important brainstem
autonomic center46. Fasudil inhibits both isoforms with approximately equal affinity77, and thus
this study is unable to address the contributions of each isoform to AngII-mediated sympathoexcitation.
At present, Fas is used clinically in Japan after acute ischemic stroke and for the prevention
of vasospasm after surgery for subarachnoid hemorrhage78,79. Another Rho kinase inhibitor,
ripasudil, is also approved in Japan for the treatment of glaucoma and ocular hypertension80. Other
clinical trials have investigated or are currently investigating Rho kinase inhibitor therapy in
psoriasis, diabetic retinopathy, pulmonary arterial hypertension, erectile dysfunction, amyotrophic
lateral sclerosis, spinal cord injury, atherosclerosis, and chronic kidney disease75.
While the clinical use of specific Rho kinase inhibitors is limited, over 30 million
Americans take statins for their cholesterol- and cardiovascular risk-reducing effects. Statins inhibit
HMG-CoA reductase, which is crucial in the synthesis of not only cholesterol but also isoprenoid
intermediates. Post-translational isoprenylation of RhoA is necessary for RhoA trafficking and
activation81, and thus, statins not only lower cholesterol but also reduce RhoA/Rho kinase activity.
Indeed, therapeutic doses of statins decrease Rho kinase activity in patients with atherosclerosis in
an LDL-independent manner82. Our lab has similarly found that statin treatment improves
autonomic function in experimental and clinical heart failure independent of LDL-lowering
effects83–87, and clinical studies in patients with hypertension and chronic kidney disease support
the sympatholytic effect of statins in humans regardless of the presence of hyperlipidemia 88–91.
Given the strong associative92–94 and experimental95,96 data linking autonomic function and
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mortality in cardiovascular disease, the sympatholytic effects of statins through Rho kinase
inhibition may be an important mechanism by which these drugs reduce cardiovascular risk.
We acknowledge that the present study has several limitations. First, it is unclear if the
dose of AngII falls within the limits of pathophysiology or if this is a strictly pharmacological dose.
Similarly, we do not know if brain tissue levels of Fas are achievable by systemic administration
of Fas in humans. Moreover, treatments were administered ICV and thus the exact location of their
action in the brain cannot be truly known, although it is likely that concentrations of all agents
would be higher near structures close to the ventricular system (e.g. SFO). Finally, the precise
mechanisms by which Rho kinase is activated by AngII and the downstream mechanisms by which
Rho kinase induces sympatho-excitation remain to be elucidated.
Activation of the RAAS and autonomic dysfunction are pathophysiological hallmarks of
cardiovascular disease. The present study shows that the pro-hypertensive, sympatho-excitatory,
and baroreflex-perturbing effects of AngII in the brain are mediated by the Rho kinase activation.
These data indicate that inhibition of the central Rho kinase pathway may act as a therapeutic brake
on the positive feedback between central RAAS activation and sympathetic outflow in many
diseases characterized by sympatho-excitation.
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Chapter II: Validation of Pulse Rate Variability as a
Surrogate for Heart Rate Variability in Chronically
Instrumented Rabbits
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Introduction
Heart rate variability (HRV) is a function of cardiac autonomic balance that is predictive
of mortality in conditions ranging from chronic heart failure to traumatic injury97,98. While clinical
standards dictate that heart rate variability must be computed from an electrocardiogram (ECG)
signal99, dozens of human studies have investigated the acceptability of pulse wave recording, by
photoplethysmography as a surrogate for heart rate variability in various physiological and disease
states100. The differences between HRV indices obtained by these two methods have led some
authors to conclude that pulse wave monitoring does not provide an acceptable signal for HRV
analysis101.
Because of its prognostic value and widespread use in clinical literature, measures of HRV
have become prevalent in animal studies, which lack the unified guidelines like those established
for humans. Frequently, so-called HRV analysis in animals is performed on data derived not from
an ECG signal but from the arterial pulse waveform obtained by a radiotelemetry implanted into a
main artery102–104. This is a much different pulse wave monitoring technique than has been
investigated in clinical studies, and it is thus important to understand how well measures of pulse
rate variability (PRV) obtained via chronically implanted radiotelemetry agree with measures of
heart rate variability (HRV) obtained via ECG. The acceptability of PRV as a surrogate for HRV
has never been systematically investigated in animals.
Measures of HRV are stratified into three categories: time-domain, frequency-domain, and
non-linear statistics. The standard deviation of normal-to-normal intervals (SDNN) is the most
widely used time domain measure and has powerful predictive value in many diseases 97,105 In the
frequency domain, the low-frequency (LF) band comprises both sympathetic and parasympathetic
oscillations while the high-frequency (HF) band is specifically modulated by parasympathetic
outflow. The low-frequency to high-frequency ratio (LF/HF), while somewhat controversial106,
remains widely used as an index of cardiac sympathovagal balance 99. Non-linear measures
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encompass a heterogeneous group of statistics, several of which quantify the entropy or complexity
of the signal. Multiscale sample entropy is one such statistic which has been used to distinguish
patients with cardiovascular pathologies from healthy subjects107–109 and is predictive of mortality
in trauma and heart failure patients110–113.
In the present study, we investigated the use of PRV as a surrogate for HRV using rabbits
chronically instrumented with both intracardiac leads and arterial pressure radiotelemeters. We
report the correlation and agreement of time domain, frequency domain, and non-linear measures
of HRV and PRV in the resting state. We also report the effect on PRV when HRV is driven to
zero by ventricular pacing. Finally, since many studies use HRV measures as an index of cardiac
autonomic status, it was important to examine the autonomic underpinnings of these two signals.
By performing cardiac autonomic blockade experiments with atropine and metoprolol, we
examined the effects of cardiac autonomic blockade on PRV and HRV.

Materials and Methods
Animals
Experiments were carried out on male New Zealand White rabbits ranging in weight from
3.3 - 4.2 kg (Charles River Laboratories, International, Wilmington, MA). All experiments were
reviewed and approved by the University of Nebraska Medical Center Institutional Animal Care
and Use Committee.

Surgical Instrumentation
All rabbits were instrumented with an implantable radiotelemeter and epicardial pacing
leads as previously described
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. In brief, the tip of the telemetry catheter (model PA-C40, Data

Sciences International, New Brighton, MN) was advanced into the abdominal aorta via the right
femoral artery and secured, allowing chronic recording of pulsatile arterial pressure and providing
the signal for PRV analysis. As part of the same surgery, a left thoracotomy was performed and a
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platinum wire pacing electrode was placed on the left ventricle of the heart and a ground wire was
secured to the left atrial appendage. The wires were tunneled beneath the skin and exited in the
mid-scapular region, providing the ECG signal for HRV analysis. The chest was evacuated, and
the thoracotomy was closed in layers. The rabbits were allowed to recover for at least two weeks
before any experiments were conducted. During this time, the animals were acclimatized to the
procedure room.

Baseline Recordings
To investigate the correlation and agreement of HRV and PRV measures in chronically
instrumented animals, baseline measurements were conducted on eight rabbits. The rabbits rested
in a plexiglass box in the dimly lit procedure room for at least 20 minutes. Pulsatile arterial
pressure, calibrated by a Dataquest A.R.T. analog system (Data Sciences International, New
Brighton, MN), and ECG were simultaneously digitized at a sampling frequency of 1 kHz via a 16channel PowerLab system (ADInstruments, Inc., Colorado Springs, CO). Each rabbit was recorded
on four separate days; however, due to an issue with the pressure telemeter in one animal, only 30
total recordings were analyzed. Five-minute, artifact-free sections of the recording were used for
HRV and PRV analysis.

Ventricular Pacing
Ventricular pacing experiments were conducted on eight rabbits to examine PRV
when HRV was driven to zero. For these experiments, the left chest, right chest, and right haunch
of each rabbit were shaved, and ECG electrodes (TenderTrace Pediatric ECG electrodes, New
Dimensions in Medicine, Dayton, Ohio) were applied to the shaved areas with conductive gel. This
signal was differentially amplified to yield the skin ECG signal, and both the skin ECG signal and
pulsatile arterial pressure were recorded for at least fifteen minutes. After this baseline recording,
a pulse generator was connected to the rabbit’s pacing leads and the heart rate was increased to 250
beats per minute, a rate higher than the maximum baseline heart rate, and held at this rate for ten to
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fifteen minutes. Five-minute, artifact-free sections pre-pace and during pacing were used for
analysis.

Cardiac Autonomic Blockade
Cardiovagal blockade with atropine, cardiac sympathetic blockade with metoprolol, and
dual blockade with both atropine and metoprolol were performed to investigate the autonomic
substrates of HRV and PRV. After local anesthesia with lidocaine, an intravenous (IV) catheter
was inserted into a marginal ear vein to allow IV administration of cardiac autonomic blockers.
Each rabbit was allowed to rest for ten minutes after the placement of the IV catheter, at which
point a 1 mL bolus of saline was given and recording of pulsatile arterial pressure and ECG was
initiated. Fifteen minutes later, a bolus of either atropine methyl bromide (0.2 mg/kg; SigmaAldrich Corp., St. Louis, MO), metoprolol bitartrate (1 mg/kg; Sigma-Aldrich Corp., St. Louis,
MO), or both was given. We have used these doses previously to block cardiac parasympathetic
and sympathetic outflow in normal and heart failure rabbits (16; 28). Five-minute, artifact-free
sections pre- and at least three minutes post-bolus were used for HRV and PRV analysis, and the
changes in time, frequency, and non-linear HRV and PRV statistics were analyzed for correlation
and agreement. The fold change was used for the LF/HF ratio and the detrended fluctuation
analysis scaling exponents.

Interval Detection and Time-Domain Indices
Both R wave and pulse wave detection was performed using the HRV module of
LabChart 7 software (ADInstruments, Inc., Colorado Springs, CO). R wave detection was
performed by finding the maximum of the ECG signal (Figure 10A). The first time derivative of
the arterial pressure signal was calculated using a 3-point window and 45-Hz low-pass filtered for
pulse wave detection (Figure 10C). Because of the large impact of pulse wave detection on
resultant PRV measures, three different fiducial points were screened for their time-domain,
frequency-domain, and non-linear fidelity to the R-R interval signal: (1) the relative maximum of
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the dAP/dt signal, denoted max dAP/dt; (2) the zero of the dAP/dt signal prior to the maximum,
corresponding to the diastolic minimum and denoted diastolic min; and (3) the zero of the dAP/dt
signal after the maximum, corresponding the systolic maximum and denoted systolic max. Per the
LabChart HRV module, the timing of the maxima of the dAP/dt and R-wave signals was computed
via three-point quadratic interpolation and the timing of zero crossings were linearly interpolated,
both with 1 µs precision. The resulting intervals were manually screened for artifacts and exported
for subsequent time-domain analysis in Kubios HRV (Biosignal Analysis and Medical Imaging
Group, University of Eastern Finland, Kuopio, Finland).

Frequency-Domain Indices
Frequency-domain analysis was carried out in Kubios HRV.

Briefly, the

tachogram was linearly interpolated at 8 Hz, 50% overlapped 1024-point windows were
transformed into the frequency domain, and the resulting power spectra were averaged per Welch’s
periodogram method. Based on previously published studies in rabbits, the 0-0.0625 Hz band was
considered very low frequency (VLF), 0.0625-0.1875 Hz was considered low frequency (LF), and
0.1875-2 Hz was considered high frequency (HF) 115,116.

Non-linear Indices
Multiscale entropy analysis used code publically available as part of PhysioNet with m=2,
r=0.15 to compute all odd scale factors from one to 39
have been derived from multiscale entropy analysis

117,118

109,113

. While many different parameters

, only two were used in this study. To

assess the fidelity of the tachograms of different pulse detection methods to non-linear aspects of
the R-R tachogram, the entropy difference (|HRV-PRV|) for each scale factor of was computed for
each baseline recording. For the remainder of the study, we used the sum of the entropy over all
the computed scales (MSE∑1-39) to represent multiscale entropy because of its prognostic value in
large patient studies98,110–112. All other non-linear indices were computed in Kubios HRV, including
Shannon, approximate, and sample entropy. Detrended fluctuation analysis (DFA) was used to
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calculate short-term (4-16 sample) and long-term (16-64 sample) scaling exponents denoted as α1
and α2 respectively.

Statistical Analysis
All group data are expressed as the mean ± SEM. All r 2 values denote the square of
Pearson’s correlation coefficient. As some correlations appeared to be driven by outliers, all points
with a Cook’s distance greater than 4/n were removed to give a corrected r 2, denoted ṙ2, where
applicable. Since Pearson’s correlation coefficient quantifies linear correlation, not agreement, we
have employed Bland-Altman plots to show accuracy and precision. To allow easier comparison
between indices, all Bland-Altman plots are displayed with percent difference on the y-axis, and
we have adopted a uniform terminology. A mean percent difference less than 5%, from 5-15%,
and above 15% are considered high, moderate, and poor accuracy respectively. Precision, defined
as 1.96 standard deviations, of less than 10%, from 10-20%, and above 20% are considered high,
moderate, and poor respectively. The percent difference in parameter X is defined as:
𝑋𝐻𝑅𝑉 − 𝑋𝑃𝑅𝑉
1
2 (𝑋𝐻𝑅𝑉 + 𝑋𝑃𝑅𝑉 )

× 100%

Bias consistency was defined as the proportion of recordings that were biased in
the same direction (i.e. XPRV < XHRV or XPRV > XHRV) as the mean. The bias consistency was then
tested against a uniform distribution using the Pearson chi-squared test with p < 0.05 considered
significant. This statistical significance formed the basis for any parameters denoted as consistently
biased (e.g. consistently overestimated or consistently underestimated).
Statistical differences between pulse detection methods and pre-and postintervention were tested by repeated measure (RM) ANOVA with pulse detection method and,
where relevant, frequency or scale factor as within-recording factors.

Post-hoc tests were

performed using the Holm-Sidak correction for multiple comparisons. Statistical differences
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between pre- and post-intervention (i.e. autonomic blockade or pacing) were tested by paired t-tests
or, where appropriate, RM ANOVA.

Other Analysis
The normalized cross-correlation, magnitude-squared coherence, and transfer
function gain between HRV and PRV tachograms were calculated using MATLAB (The
Mathworks, Inc., Natick, MA). The residual PRV power spectral density for each animal was
calculated by subtracting the post-pace HRV power spectrum from the post-pace PRV power
spectrum. The percent of PRV power that was independent of HRV was defined as
1−

𝐺(𝑓) ∗ 𝐻𝑅𝑉(𝑓)
𝑃𝑅𝑉(𝑓)

where G(f) is the transfer function gain and HRV(f) and PRV(f) denote the HRV and PRV
autospectra.

For all MATLAB frequency domain calculations, tachograms were linearly

interpolated at 8 Hz, and the corresponding spectra were computed by Welch’s periodogram
method using 256-point Hamming-windowed segments with 50% overlap.
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Figure 10 – Pulse Interval Detection Method Screening
Representative tracings of (A) the electrocardiogram signal, (B) the arterial pressure signal with
different fiducial points, and (C) the first time derivative of the arterial pressure signal. The detected
R waves and pulse waves are shown with dotted lines. (C) Pulse intervals for the three different arterial
pulse fiducial points, (top) max dAP/dt, (middle) diastolic minimum, and (bottom) systolic maximum,
are displayed. (D) Cross-correlation of the tachogram for each pulse detection method with the R-R
interval tachogram. (E) Magnitude-squared coherence between the spectrogram for each pulse
detection method and the R-R interval spectrogram. (F) Entropy difference between the R-R interval
tachogram and the pulse interval tachogram over multiple scale factors. All values are displayed as
mean ± SEM, n = 30. ***, p < 0.001 vs. diastolic minimum; #, p < 0.05 vs. systolic maximum by 2way RMANOVA with post-hoc Holm-Sidak tests.
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Results
Pulse Interval Detection Method
Three different fiducial points derived from the dAP/dt signal were screened using timedomain, frequency-domain, and non-linear measures to identify the best pulse interval detection
method. In the time domain (Figure 10D), the normalized cross-correlation was very close to 1 for
all methods, indicating that the pulse interval tachograms are largely a time-lagged function of the
R-R tachogram, with no statistically significant effect of fiducial point on cross-correlation. In the
frequency domain (Figure 10E), magnitude-squared coherence with the R-R spectra shows a
similar trend for all methods, starting near 1 and falling as frequency increases. More important,
the coherence was significantly higher for dAP/dt max than for the other two fiducial points. In
the non-linear domain (Figure 10F), the pulse detection methods did not significantly affect the
difference in entropy from that of the R-R tachogram over multiple scale factors. Thus, because of
its superiority in the frequency domain, the maximum of the dAP/dt signal was used to calculate
PRV for the remainder of the study. For completeness, tables of data for the systolic maximum and
diastolic minimum fiducial points are included in Table 1 and Table 2, respectively, of Appendix
A.
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Table 9 – Indices of HRV and PRV for 30 baseline recordings
Category
Time Domain

PRV

Heart rate (bpm)

187 ± 4

187 ± 4

SDNN (ms)

26.8 ± 2.6

27.4 ± 2.7

-2.03 ± 2.98

29/30***

0.999 (0.999)

RMSSD (ms)

25.1 ± 3.1

25.8 ± 3.3

-2.56 ± 5.70

18/30

0.996 (0.995)

847 ± 165

883 ± 177

-3.32 ± 6.51

27/30***

0.999 (0.999)

299 ± 55.7

302 ± 57

-0.48 ± 1.53

16/30

0.999 (1.00)

2

2

VLF Power (ms )
2

-0.0422 ± 0.0807 27/30***

1.00

LF Power (ms )

102 ± 18

105 ± 18

-3.06 ± 2.16

28/30***

0.999 (0.999)

LF Power (nu)

25.8 ± 2.5

25.2 ± 2.4

2.33 ± 9.99

21/30*

0.989 (0.994)

HF Power (ms )

444 ± 103

473 ± 112

-6.5 ± 15.2

26/30***

0.998 (0.997)

HF Power (nu)

73.6 ± 2.5

74.3 ± 2.4

-1.07 ± 4.98

21/30*

0.988 (0.994)

3.39 ± 14.33

21/30*

0.986 (0.996)

2

LF/HF Ratio

Non-linear

r2 (ṙ2)

HRV

Total Power (ms )

Frequency Domain

Bland-Altman
Bias
Interval (%) Consistency

Index

0.413 ± 0.062 0.396 ± 0.059

MSE∑1-39

29.9 ± 0.7

30.0 ± 0.7

-0.59 ± 5.86

16/30

0.947 (0.970)

Shannon Entropy

3.81 ± 0.09

3.79 ± 0.09

0.59 ± 3.38

20/30

0.989 (0.987)

Approximate Entropy

1.24 ± 0.04

1.26 ± 0.03

-1.83 ± 7.44

19/30

0.953 (0.969)

-2.3 ± 12.2

19/30

0.949 (0.964)

3.7 ± 22.7

21/30*

0.654 (0.636)

1.36 ± 6.97

24/30**

0.971 (0.986)

Sample Entropy
1.26 ± 0.06
1.28 ± 0.05
DFA short-term (α1) 0.949 ± 0.032 0.914 ± 0.030
DFA long-term (α2) 0.948 ± 0.034 0.935 ± 0.033

Values are displayed as mean ± SEM, Bland-Altman intervals (mean bias ± 95% limits of agreement), bias
consistency, and pairwise coefficient of determination (r2) between HRV and PRV values. Where applicable,
the r2 values after removal of points with a Cook’s distance > 0.133 (denoted ṙ2) are displayed in parentheses.
* p < 0.05, ** p < 0.01, *** p < 0.001 by Pearson’s χ² test.
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Baseline Time-Domain Indices
As Figure 11A illustrates, tachograms obtained from ECG and arterial pulse signals are
visually very similar. Figure 11B shows a very high correlation between PRV and HRV measures
of SDNN. Bland-Altman plotting (Figure 11C) reveals that PRV consistently overestimates
SDNN, but PRV SDNN is still highly accurate and precise. In the baseline condition, all time
domain indices of PRV show a strong correlation with HRV measures as well as high precision
and accuracy (Table 9).

Figure 11 – Time Domain Statistics at Baseline
(A) Representative HRV (solid gray line) and PRV (dotted black line) tachograms. (B) Scatter plot of PRV SDNN versus
HRV SDNN with line of best fit (solid gray) and line of equality (dotted black). Points with Cook’s d > 4/n are displayed
as circles. (C) Bland-Altman plot showing the percent difference in SDNN (HRV-PRV) versus the pairwise mean
SDNN with the mean bias (solid horizontal line) and the upper and lower 95% limits of agreement (dashed horizontal
lines). r2, Pearson’s mean-squared pairwise coefficient of determination; ṙ2, Pearson’s mean-squared pairwise coefficient
of determination excluding points with Cook’s d > 0.133.
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Figure 12 – Frequency Domain Statistics at Baseline
(A) Representative HRV (solid gray line) and PRV (dotted black line) spectra on a semilog plot with shading denoting
VLF, LF, and HF frequencies. (B) Scatter plot of PRV LF/HF ratio versus HRV LF/HF ratio with line of best fit (solid
gray) and line of equality (dotted black). (C) Bland-Altman plot showing the percent difference in LF/HF (HRV-PRV)
versus the pairwise mean LF/HF with the mean bias (solid line) and the upper and lower 95% limits of agreement (dashed
lines). r2, Pearson’s mean-squared pairwise coefficient of determination; ṙ2, Pearson’s mean-squared pairwise
coefficient of determination excluding points with Cook’s d > 0.133
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Baseline Frequency-Domain Indices
Figure 12A illustrates the visual similarity between the HRV and PRV power
spectra for one recording. As would be expected from the coherence plots (Figure 10E), the spectra
are very similar at lower frequencies and become more disparate at higher frequencies. As Figure
Figure 12B shows, the PRV LF/HF ratio correlates strongly with the HRV measure. Bland-Altman
plotting (Figure 12C) illustrates that PRV consistently underestimates the LF/HF ratio but still
shows high accuracy and precision. The underestimation of LF/HF results from the fact that, while
PRV consistently exaggerates the power in all frequency measures except the very-low frequency
range, this tendency is greatest for high frequency power. All other spectral measures of PRV show
high accuracy and precision in resting rabbits except high frequency power, which is only
moderately accurate and precise (Table 9).
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Figure 13 – Non-linear Statistics at Baseline
(A) PRV and HRV sample entropy at multiple scale factors for a single recording. (B) PRV and HRV sample entropy
at multiple scale factors for all recordings displayed as mean ± SEM, n = 30. (C) Scatter plot of PRV multiscale entropy
(the sum over odd scale factors from 1-39) versus HRV multiscale entropy with line of best fit (solid gray) and line of
equality (dotted black). (D) Bland-Altman plot showing the percent difference in multiscale entropy (HRV-PRV) versus
the pairwise mean multiscale entropy with the mean bias (solid line) and the upper and lower 95% limits of agreement
(dashed lines). r2, Pearson’s mean-squared pairwise coefficient of determination; ṙ2, Pearson’s mean-squared pairwise
coefficient of determination excluding points with Cook’s d > 0.133.
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Baseline Non-linear Indices
Figure 13A illustrates the visual difference between HRV and PRV sample entropy at
different scale factors for a single recording. These differences are not apparent in the group data
(Figure 13B). Although the correlation between HRV and PRV multiscale sample entropy is strong
(Figure 13C), it is clearly not as robust as the correlations for time- and frequency-domain indices.
Again contrasting from time- and frequency-domain measures, PRV multiscale entropy is not
consistently biased (Figure 13D, (Table 9). The Bland-Altman plot also shows high accuracy and
precision for multiscale entropy (Figure 13D). While most of the PRV non-linear indices show a
strong correlation with corresponding HRV indices, these relationships tend to be notably weaker
than those observed for time- and frequency-domain measures (Table 9). The short-term detrended
fluctuation analysis scaling exponent (α1) shows a particularly poor correlation. In the baseline
condition, all non-linear measures have high accuracy, and all but α1 and sample entropy also have
high precision.
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Figure 14 – Transfer Function Analysis and Ventricular Pacing Experiments
. (A) Transfer function gain, G(f), the PRV:HRV ratio, PRV(f)/HRV(f), and HRV-independent power as a function of
frequency at baseline, n = 30. (B) The effect of pacing on HRV and PRV SDNN, n = 8. (C) The effect of ventricular
pacing on the coherence between HRV and PRV as a function of frequency, n = 8. (D) The residual PRV power spectrum
for paced rabbits, n = 8.
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Ventricular Pacing
Because PRV consistently overestimated both time- and frequency-domain measures of
HRV at baseline, we investigated if PRV was simply amplifying HRV or if other, HRVindependent rhythms accounted for this increased variability. Figure 14A shows that transfer
function gain is greater than 1 from 0 Hz to 0.375 Hz, indicating that PRV does indeed amplify
HRV, albeit modestly, over the frequency range containing the vast majority of the HRV power.
Interestingly, however, the ratio of PRV power to HRV power demonstrates that this amplification
does not completely explain the tendency of PRV to overestimate HRV, and the percent of PRV
power that is independent of HRV increases with frequency until stabilizing at approximately 1.25
Hz.
Ventricular pacing experiments were conducted to assess the HRV-independent rhythms
of PRV by driving HRV to zero. As Figure 14B shows, ventricular pacing almost completely
eliminates HRV (post-pace SDNN = 0.32 ± 0.04 ms) and significantly attenuates PRV. Still, PRV
remains non-negligible, indicating a minimum PRV SDNN of 1.47 ± 0.13 ms. Figure 14C displays
the magnitude-squared coherence for pre-pace and paced conditions. As expected, the coherence
equals 1 at 0 Hz, indicating the mean rate is the same for PRV and HRV. The coherence sharply
declines until 0.25 Hz, beyond which point the coherence remains very low, indicating the absence
of a relationship between paced PRV and HRV for these frequencies. Subtraction of the paced
heart rate spectrogram from the pace pulse rate spectrogram yields the residual PRV spectrum,
(Figure 14D) which showed a peak at 1.25 Hz. This HRV-independent rhythm could explain some
of the tendency of PRV to specifically overestimate the high-frequency component of the HRV
spectrum. It could also explain the trend of magnitude-squared coherence (Figure 10, Figure 14C)
to fall as frequency increases and this HRV-independent variability constitutes a greater proportion
of PRV power.
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Table 10 – Changes in indices of HRV and PRV after cardiac autonomic blockade

Category
Time
Domain

Atropine
Bland-Altman
Interval (%)

Index

r2 (ṙ2)

Metoprolol
Bland-Altman
Interval (%)

r2 (ṙ2)

Double Blockade
Bland-Altman
Interval (%)
r2 (ṙ2)

∆HR (bpm)

0.209 ± 0.476 1.00 (1.00)

0.460 ± 6.14

1.00 (1.00)

0.088 ± 0.255 1.00 (1.00)

∆SDNN (ms)

-2.03 ± 4.95

0.995 (0.999)

2.28 ± 7.50

0.999

-0.37 ± 3.88

0.997 (0.999)

∆RMSSD (ms)
∆Total Power (ms2)

-0.2 ± 10.4
-4.17 ± 9.12

0.981 (0.956)
0.993 (0.996)

-3.6 ± 19.7
-0.22 ± 8.37

0.992 (0.996)
1.00 (0.998)

3.6 ± 12.1
-2.73 ± 4.68

0.981 (0.992)
1.00 (0.999)

∆VLF Power (ms2)

-0.12 ± 3.26

0.998

-3.61 ± 13.2

0.999

-0.43 ± 2.52

0.999 (1.00)

-3.71 ± 9.75

0.998 (0.998)

2.6 ± 18.9

0.999 (1.00)

-3.13 ± 2.90

1.00 (1.00)

-49.5 ± 101.5

0.900

0.0 ± 17.2

0.990 (0.999)

-458 ± 2545

0.337 (0.065)

-6.84 ± 13.97

0.996 (0.991)

-2.1 ± 10.9

1.00 (0.999)

-3.67 ± 6.78

1.00 (0.998)

∆HF Power (nu)

50.3 ± 202

0.901

-0.35 ± 18.5

0.998 (0.999)

2277 ± 1517

0.353 (0.040)

LF/HF Fold Change

-55.5 ± 106.3

0.996 (0.734)

-4.6 ± 11.5

0.987 (0.971)

-95.7 ± 64.1

0.045 (0.015)

∆MSE∑1-39

61 ± 211

0.760 (0.843)

-89 ± 1453

0.553 (0.618)

153 ± 412

0.761 (0.258)

∆Shannon Entropy

-16 ± 291

0.776 (0.636)

-2.32 ± 21.8

0.997

-201 ± 600

0.691

0.653 (0.631)

-81 ± 542

0.858 (0.581)

-100 ± 872

0.616

0.613 (0.339)

-8 ± 155

0.914 (0.832)

-294 ± 2287

0.612

0.505 (0.673)

4.95 ± 4.90

0.905

38.4 ± 51.0

0.709

0.677 (0.542)

-0.44 ± 3.62

0.955 (0.980)

15.4 ± 27.3

0.802 (0.619)

∆LF Power (ms )
Frequency
Domain ∆LF Power (nu)
∆HF Power (ms2)
2

Non-linear ∆Approximate Entropy -34 ± 233
∆Sample Entropy
-62 ± 279
DFA α1 Fold Change
-3.3 ± 96.3
DFA α2 Fold Change
-4.8 ± 27.6

Agreement and correlation of the changes in indices of HRV and PRV after autonomic blockade are displayed as
Bland-Altman intervals (mean bias ± 95% limits of agreement) and pairwise coefficient of determination (r 2). Where
applicable, the r2 values after removal of points with a Cook’s distance > 0.5 (denoted ṙ2) are shown in parentheses.
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Table 11 – Indices of HRV and PRV before and after cardiac autonomic blockade

Category
Time
Domain
Frequency
Domain
Non-linear
Time
Domain
Frequency
Domain
Non-linear
Time
Domain
Frequency
Domain
Non-linear

Before Atropine
After Atropine
Index
HRV
PRV
HRV
PRV
HR (bpm)
178 ± 6
178 ± 6
233 ± 8***
233 ± 8***
SDNN (ms)
26.4 ± 2.4 27.2 ± 2.8
4.27 ± 0.70*** 4.48 ± 0.62***
Total Power (ms2) 767 ± 155 820 ± 188
13.3 ± 3.3**
14.3 ± 3.3**
2
LF Power (ms ) 113 ± 20
118 ± 21
2.3 ± 1.0**
2.5 ± 1.1**
2
HF Power (ms ) 396 ± 121 444 ± 154
1.04 ± 0.30*
1.80 ± 0.31*
MSE∑1-39
36.4 ± 3.1 36.7 ± 4.1
28.4 ± 5.3
24.1 ± 2.7
Before Metoprolol
After Metoprolol
HR (bpm)
191 ± 6
191 ± 6
186 ± 4
186 ± 4
SDNN (ms)
20.8 ± 3.0 21.0 ± 3.0
16.4 ± 2.6*
16.6 ± 2.6*
2
Total Power (ms ) 477 ± 168 491 ± 175
272 ± 83
283 ± 89
LF Power (ms2) 50.1 ± 11.7 51.4 ± 12.1
56.5 ± 21.0
57.7 ± 21.6
2
HF Power (ms ) 252 ± 121 264 ± 128
121 ± 40
129 ± 44
MSE∑1-39
39.1 ± 2.6 39.3 ± 2.8
45.6 ± 5.7
44.5 ± 4.66
Before Double Blockade
After Double Blockade
HR (bpm)
176 ± 5
177 ± 5
234 ± 7***
234 ± 7***
SDNN (ms)
28.0 ± 2.6 28.4 ± 2.7
1.51 ± 0.12*** 1.82 ± 0.15***
Total Power (ms2) 994 ± 279 1031 ± 295
1.45 ± 0.14*
2.25 ± 0.26*
LF Power (ms2) 116 ± 29
121 ± 31
0.133 ± 0.027** 0.149 ±
HF Power (ms2) 603 ± 215 634 ± 227
0.445 ± 0.098* 0.028**
1.22 ± 0.230*
MSE∑1-39
39.0 ± 3.9 43.2 ± 4.5
34.3 ± 4.9
28.1 ± 3.5

Values are displayed as mean ± SEM. *, **, ***, p < 0.05, p < 0.01, p <0.001 vs.
before blockade
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Figure 15 – Effects of Cardiac Autonomic Blockade on SDNN
Scatter plots of the change in PRV SDNN versus change in HRV SDNN after (A) atropine, (B) metoprolol, and (C) dual
blockade with lines of best fit (solid gray) and lines of equality (dotted black). Bland-Altman plots showing the percent
difference in HRV and PRV ∆SDNN (HRV-PRV) versus the pairwise mean ∆SDNN after (D) atropine, (E) metoprolol,
and (F) dual blockade with the mean bias (solid lines) and the upper and lower 95% limits of agreement (dashed lines).
r2, Pearson’s mean-squared pairwise coefficient of determination; ṙ2, Pearson’s mean-squared pairwise coefficient of
determination excluding points with Cook’s d > 0.5.
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Cardiac Autonomic Blockade – Time Domain
Since many investigators use HRV as an index of cardiac autonomic balance, it is important
that changes in cardiac autonomic tone are faithfully represented by PRV. Figure 15A-C shows
the strong correlations between the changes in PRV SDNN and HRV SDNN after cardiovagal
blockade with atropine, cardiac sympathetic blockade with metoprolol, and combined blockade
respectively. Bland-Altman plots (Figure 15D-F) show a high accuracy of the change in PRV
SDNN after autonomic blockade. The precision is also high for atropine- and dual blockadeeffected changes in SDNN but only moderate for metoprolol, mainly due to one outlier. Also of
note, PRV consistently (p < 0.01) overestimates the atropine-mediated change in SDNN. Changes
in heart rate show high accuracy and precision whereas RMSSD shows high accuracy and moderate
precision for each autonomic blockade intervention, and both show strong correlations (Table 10).
Overall, PRV accurately reflects changes in HRV time-domain measures that result from acute
changes in cardiac autonomic tone.
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Figure 16 – Effects of Cardiac Autonomic Blockade on Spectral Indices
Scatter plots of (A) the change in PRV high-frequency power versus the change in HRV high-frequency power after
atropine, (B) the change in PRV low-frequency power versus the change in HRV low-frequency power after
metoprolol, and (C) the change in PRV total power versus the change in HRV total power after dual blockade with
lines of best fit (solid gray) and lines of equality (dotted black). Bland-Altman plots showing the percent difference
in (D) HRV and PRV ∆HF power (HRV-PRV) versus the pairwise mean ∆HF after atropine, (E) HRV and PRV ∆LF
power (HRV-PRV) versus the pairwise mean ∆LF after metoprolol, and (F) HRV and PRV change in total power
(HRV-PRV) versus the pairwise mean ∆TP after dual blockade with the mean bias (solid lines) and the upper and
lower 95% limits of agreement (dashed lines). r2, Pearson’s mean-squared pairwise coefficient of determination; ṙ2,
Pearson’s mean-squared pairwise coefficient of determination excluding points with Cook’s d > 0.5.
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Cardiac Autonomic Blockade – Frequency Domain
Atropine administration nearly eliminates high-frequency power, and, as Figure 16A
shows, the change in HRV and PRV high-frequency power after atropine is very strongly
correlated, but the slope of this relationship is greater than that of the line of equality. The BlandAltman plot (Figure 16D) shows that the change in PRV high-frequency power is a moderately
accurate and precise surrogate for the change in HRV high-frequency power after atropine. More
specifically, PRV consistently (p < 0.05) exaggerates the change in high-frequency power, likely
due to the increased PRV high-frequency power at baseline. Similarly, the correlation between
atropine-mediated changes in the absolute power of frequency domain measures of HRV and PRV
is very robust and these measures show high accuracy and precision. However, PRV highfrequency power remains higher than HRV high-frequency power (Table 11), likely due to the
presence of intrinsic PRV as revealed by our ventricular pacing experiment. While the magnitude
of this intrinsic PRV is small, it now constitutes a large proportion of the greatly attenuated total
power and exerts negative effects on the normalized powers and LF/HF ratio. As a result, the
correlations and agreements of the change in normalized powers and LF/HF ratio fold change are
very poor (Table 10).
Metoprolol administration did not have a robust, consistent effect on low-frequency power
in all animals; however, PRV reflected the changes in HRV low-frequency power after metoprolol
for each rabbit in a highly accurate and moderately precise manner (Figure 16E). Here, the
correlation between the PRV and HRV spectral changes was strong for both normalized and
absolute measures (Figure 16B, Table 10). In addition, the changes in other HRV and PRV spectral
measures after metoprolol showed moderate to high accuracy and precision (Table 10).
Combined autonomic blockade attenuates total power, and the decrease in PRV total power
correlates very well with the change in HRV power (Figure 16C). Bland-Altman plotting shows
the change in PRV power to be a highly accurate, highly precise estimate of the change in HRV
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power (Figure 16D). It is also clear that PRV consistently (p < 0.05) exaggerates the decrease in
power, likely due to the elevated PRV total power at baseline. Changes in other HRV and PRV
frequency-domain statistics demonstrated robust correlations and high accuracy and precision with
the notable exception of normalized measures and the LF/HF ratio. These measures showed very
poor accuracy and precision; as with atropine, this is likely due to the exaggerated influence of
intrinsic PRV when HRV is dramatically decreased by autonomic blockade.

Cardiac Autonomic Blockade – Non-linear Measures
Autonomic blockade-mediated changes in the non-linear measure multiscale
entropy differed considerably between PRV and HRV. As Figure 17A-C show, the correlations
between the change in PRV multiscale entropy and the change in HRV multiscale entropy are very
modest for all three of the autonomic blockade conditions. Moreover, the slopes of the best-fit
lines are visibly much less than those of the lines of equality. The Bland-Altman plots (Figure
17D-F) show very poor accuracy and very poor precision for each of the conditions. Similarly
disappointing performance was observed with changes in other measures of entropy, which were
plagued by poor precision after all interventions (Table 10). The fold changes in the DFA scaling
exponents showed mixed strength of agreement, with the long-term statistic α2 performing the best
of the non-linear measures with high accuracy and moderate to high precision after single blockade.
Correlations for all non-linear measures varied widely between conditions but were clearly much
lower than the time- and non-normalized frequency-domain measures (Table 10).
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Figure 17 – Effects of Cardiac Autonomic Blockade on Multiscale Entropy
Scatter plots of the change in PRV multiscale entropy versus change in HRV multiscale entropy after (A) atropine,
(B) metoprolol, and (C) dual blockade with lines of best fit (solid gray) and lines of equality (dotted black). BlandAltman plots showing the percent difference in HRV and PRV change in multiscale entropy (HRV-PRV) versus
the pairwise mean change in multiscale entropy after (D) atropine, (E) metoprolol, and (F) dual blockade with the
mean bias (solid lines) and the upper and lower 95% limits of agreement (dashed lines). r2, Pearson’s meansquared pairwise coefficient of determination; ṙ2, Pearson’s mean-squared pairwise coefficient of determination
excluding points with Cook’s d > 0.5.
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Discussion
In general, we found that invasively acquired PRV overestimates corresponding HRV
parameters in both the time and frequency domains in resting rabbits. Moreover, while PRV
exaggerates HRV power in all frequencies, this effect is most pronounced in the high-frequency
range, and interrelated measures like normalized LF and the LF/HF ratio are accordingly decreased
when assessed by PRV. While we have shown by transfer function analysis that some of this
overestimation is due to amplification of HRV spectral components, we have also shown that HRVindependent oscillations are important as well. This additional variability must come from
variations in either pre-ejection time (i.e. the time after ventricular depolarization but before
opening of the aortic valve) or pulse transit time (i.e. the time required for the arterial pulse to
propagate from the aortic valve to the telemetry catheter). Pre-ejection time is largely a function
of contractility, preload, and afterload while pulse transit time is affected by pulse pressure and
arterial elasticity

119

. The cyclic effects of respiration on venous return, preload, stroke volume,

and thus pulse pressure are believed to account for much of the variability in pre-ejection time and
pulse transit time. This is supported by studies that observed peaks in the spectrum of the difference
between pulse intervals and R-R intervals in the respiratory frequency range

101,120

as well as the

aforementioned tendency for PRV to overestimate HRV specifically in the high frequency range.
Although respiration was not measured in this study, a spontaneous respiratory frequency of 1.25
Hz is reasonable for resting rabbits and is the most likely explanation for the residual PRV peak
observed during ventricular pacing.
These findings agree with studies using non-invasive methods to calculate time and
frequency measures of PRV in resting human subjects

100

. Compared to previous studies using

similar pulse detection algorithms, our invasively acquired PRV data show better correlations and
better agreement with HRV measures than PRV sampled by non-invasive methods120–122. This is
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likely due to the more proximal location of the pulse wave sensor (i.e. aorta versus finger), which
in turn decreases the variability in pulse transit time.
A previous study performed by Bhatia et al showed that low sampling rates negatively
impact the accuracy of indices of heart rate and blood pressure variability in rats and mice but that
accuracy can be restored by interpolation of the downsampled signal123. This is particularly
relevant to our study as the DSI PA-C40 pressure telemetry has an internal sampling rate of 500
Hz whereas the ECG was digitized at 1 kHz. As the signal used for pulse interval detection was
resampled with 1 µs (i.e. 1 MHz) precision, we do not believe this was a confounding factor in our
study. Interestingly, these authors also recorded simultaneous ECG and arterial pressure in the rats
in this study and found that the SDNN, RMSSD, triangular index, and low-frequency power, but
not high-frequency power, could be estimated from the arterial pulse signal with less than 10%
difference from the HRV measures. In our study, the ability of PRV to estimate HRV highfrequency power was better (7.01% difference using the same formula). This may be due to species
differences or due to the poorer coherence of the diastolic minimum fiducial point used in this
study.
The effect of pulse detection on the correlation and agreement of non-invasive PRV and
HRV measures in humans has been investigated previously 124. These authors found that a tangent
method based on the timing of the max dAP/dt was superior to both the diastolic minimum and
max d2AP/dt. Our results similarly show the frequency-domain superiority of the max dAP/dt to
the diastolic minimum and systolic maximum as a fiducial point, although we have employed more
accessible and computationally simpler techniques than these authors.
While, at baseline, non-linear PRV measures showed high accuracy but mixed precision in
approximating corresponding HRV measures, none showed the highly robust correlations (r 2 >
0.99) like those observed for time- and non-normalized frequency-domain measures. Our attempts
to augment the linearity of the relationship by plotting the log of PRV parameters vs. the log of
HRV parameters did not substantially improve these correlations (data not shown). Moreover,
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changes in most non-linear measures of PRV after autonomic blockade were shown to be a very
poor surrogate for changes in HRV non-linear measures, suffering from poor accuracy, precision,
and weak correlations. We thus do not recommend the use of PRV as a surrogate for HRV if nonlinear measures are a primary endpoint, especially in studies that manipulate autonomic tone.
One unexpected finding in our study was the lack of a strong change in low-frequency
power after beta-blockade, which differs from previous studies in rabbits104. While this dose of
metoprolol results in a profound bradycardia in rabbits with chronic heart failure(16), it did not
significantly decrease heart rate (p = 0.180) in this group of animals. Others have also reported the
absence of a frequency domain change after beta-blockade in normal animals102. We believe the
lack of a clear bradycardia and spectral effect after metoprolol reflects low sympathetic tone in
these healthy, resting rabbits.
It is important to point out that the criteria for high, moderate, and low accuracy and
precision were fixed prior to analysis in an arbitrary manner. How much two methods can differ
without becoming problematic depends on the intended application and is not a question that
statistical methods can answer125. Thus, it is important that investigators wishing to use PRV as a
surrogate for HRV in chronically instrumented animals look critically at the data presented here
and decide for themselves whether or not the demonstrated agreements and correlations are
sufficient for their purposes.
For investigators interested in using invasively acquired PRV measures as an index of
cardiac autonomic balance, these data also pose an important question of the necessity for
agreement versus correlation. Clearly, changes in time-domain and absolute spectral power
measures of PRV explain autonomic blockade-mediated changes in corresponding HRV measures
in a very robust manner (i.e. coefficient of determination greater than 0.99). For studies in which
the principal purpose of PRV analysis is the assessment of cardiac autonomic state, these robust
linear relationships may be sufficient to justify the use of PRV. We advise special attention for
using PRV in conditions in which HRV is very low, as residual PRV may constitute an
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unacceptably high proportion of total PRV, and in conditions or maneuvers that modify vagal tone,
as PRV appears to amplify these changes.
Finally, we would like to point out some of the limitations of our study.

Using

pharmacological autonomic blockade is a convenient, acute method to manipulate cardiac
sympathovagal balance, but these findings do not address the ability of PRV to reflect chronic
changes in HRV. Similarly, it is difficult to generalize these findings in healthy animals to disease
models, including those with autonomic dysfunction and cardiorespiratory disorders. Moreover,
given the species-specific nature of HRV rhythms, it is unclear how the observed trends translate
to other animal models like mice, rats, and dogs. Monitoring respiratory frequency would also have
provided important insight into the source of intrinsic PRV.
In summary, invasively acquired PRV is generally an accurate and precise surrogate for
time, frequency, and some non-linear measures of HRV at baseline. The tendency for PRV to
slightly overestimate HRV parameters in the time and frequency domains can be explained both
by amplification of HRV oscillations as well as its composition by HRV-independent rhythms.
Furthermore, while robust correlations and moderate to high agreement exist between the changes
in time- and absolute frequency-domain PRV and HRV parameters after autonomic blockade, most
non-linear parameters show very poor agreement after administration of autonomic blockers. Thus,
invasively acquired PRV is likely an acceptable surrogate for HRV except when non-linear
measures are a primary endpoint or when HRV is greatly reduced such that HRV-independent
oscillations predominate. These findings are relevant to investigators who wish to use PRV to
compute HRV measures as well as to the interpretation of countless studies that have already been
published based on the assumption that PRV is an acceptable surrogate for HRV.
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Chapter III: Physiological Renal Sympathetic
Vasomotion
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Introduction
The maintenance of renal blood flow (RBF) is crucial for renal function, and the kidney is
accordingly endowed with two powerful autoregulatory mechanisms, tubuloglomerular feedback
(TGF) and the myogenic response (MR), which are widely appreciated as important controllers of
RBF126. TGF is a mechanism that is unique to the kidney whereby changes in RBF-dependent NaCl
flux at the end of the thick ascending limb are sensed by macula densa cells and transduced to
modulate the diameter of the anatomically juxtaposed afferent arteriole. The MR, observed in other
vascular beds but particularly strong in the kidney, senses changes in transmural pressure and
responds by adjusting afferent arteriolar diameter to preserve constant RBF. Together these
mechanisms maintain RBF and glomerular filtration rate over a wide range of perfusion pressures
by modulating renal vascular conductance (RVC).
Conversely, the classic dogma maintains that the renal nerves are quiescent in the control
of RBF in a normal, healthy state, causing vasoconstriction and a reduction in RBF only in response
to experimental stimuli or in the setting of disease. This dogma, based mainly on steady-state
measurements of mean RBF over minutes persists despite the fact that dynamic approaches have
revealed the involvement of the renal nerves in the beat-to-beat dynamic regulation of RBF.

Steady-State Studies
The dogma that the renal nerves do not play a role in the physiological regulation of RBF
developed over many decades. These studies made important contributions to our understanding of
sympathetic neural control of renal function, but erred in assuming that steady-state (i.e. static or
mean) measures of RBF could fully capture what we know today to be a dynamic process. To be
fair, many of these studies preceded modern technologies for the assessment of RBF and relied on
a much less complete understanding of renal autoregulation, and they should be viewed in this
context. Today, the dogma rests primarily on findings from two sets of studies. We will briefly
present the main findings of these studies.
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One set of studies involves electrical stimulation of the renal nerves, which showed that
low stimulation frequencies were sufficient to cause renin release, intermediate stimulation
frequencies stimulated sodium reabsorption, and high stimulation frequencies were necessary to
decrease RBF127–130. This data was interpreted to mean that the renal nerves play a role in basal
renin release and sodium reabsorption, but not RBF control. We raise two problems with this line
of thinking. The first problem is that steady-state electrical stimulation of the renal nerve does not
reflect physiological control of RSNA in any way. Thus, such a paradigm, while powerful for
addressing whether or not a parameter can be affected by RSNA, is ill-suited for addressing how
the parameter is normally regulated by physiological sympathetic outflow. The second problem is
that all of these studies looked at mean RBF averaged over minutes. As described previously, renal
perfusion is also controlled by powerful autoregulatory mechanisms which are very effective in
buffering changes in RBF over such a time span. Indeed, one study cited in support of this dogma
reported that renal nerve stimulation results in an immediate drop in RBF, presumably the rapid
effect of renal sympathetic vasoconstriction, which then recovers to pre-stimulation levels,
presumably due to the compensatory vasodilatation effected by slower autoregulatory
mechanisms127. Thus, these stimulation intensities do not correspond to the minimum threshold
required to initiate renal vasoconstriction; instead, they represent the stimulation threshold at which
the autoregulatory mechanisms fail.
The second set of studies supporting this dogma comes from some studies in chronically
denervated dogs and rabbits that failed to detect a statistically significant difference between
innervated and denervated kidneys131–133. We again raise two issues. The first is statistical; the
second is physiological.
It is a fundamental aspect of statistical hypothesis testing to understand that the result
obtained from an unpowered inference test is of little value. In the case that the null hypothesis is
rejected, one does not know if no difference exists or if the test was simply underpowered, and it
is wrong to simply assume the former. In this application: does removal of the renal nerves truly
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not affect RBF or have previous tests simply been underpowered? Because of the high variability
in RBF between kidneys, the latter is the case. A previous study of interest showed that the
innervated (INV) kidney of a conscious dog has a mean PAH clearance of 187 mL/min with a
standard deviation of 28 mL/min (n = 6)133 while a decent-sized (n = 10) study showed that INV
kidneys of conscious rabbits have a resting RBF with a mean of 50 mL/min and standard deviation
of 15.8 mL/min134. If one considers a physiological difference in RBF to be a difference of 15%
(i.e. the renal nerves decrease RVC by 15%), then one would need to perform a study with 64 dogs
or 71 rabbits per group in order to have 80% power to detect a 15% change in mean RBF by twotailed t-test with α = 0.05 given the high degree of variability in basal RBF. No study of this size
has ever been attempted, and the vast majority are not even within one order of magnitude of the
requisite sample sizes. This critique also applies to the numerous studies where RBF was increased
in denervated animals as underpowered studies are also prone to Type I (false positive) errors as
well as Type II (false negative) errors.
The physiological argument is that, again, mean RBF is autoregulated, so the effect of
removing the renal nerves does not reflect the sympathetic contribution to mean RBF as the
powerful autoregulatory mechanisms exist to buffer such disturbances in mean RBF. Such an
interpretation neglects not only the role of the renal nerves but also the strength of autoregulatory
mechanisms. Since autoregulatory mechanisms can modulate RVC over two-fold126, even a large
sympathetic contribution to basal RVC could be completely masked by compensation by TGF and
MR. Indeed, we regard findings from both electrical stimulation and chronic denervation studies
as a testament to the power of renal autoregulation, rather than as evidence for the absence of
physiological renal sympathetic control of RBF.
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Figure 18 – RSNA is Dynamically Controlled
14-second recording of AP, raw RSNA, and integrated RSNA in a healthy, calmly resting rabbit
one-week after RSNA electrode implantation. Note the dynamic nature of RSNA and the strong
baroreflex control of RSNA, with the amplitude and incidence of RSNA bursts strongly
corresponding to DBP.
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Dynamic Approaches for a Dynamic Phenomenon
Following the diffusion of techniques allowing for chronic, conscious recordings of RSNA,
the dynamic nature of RSNA became impossible to ignore. Figure 18 shows a 14-second sample
of a recording from a conscious rabbit instrumented with RSNA electrodes that plainly
demonstrates rhythmicity, beat-to-beat variability, and baroreflex control of RSNA, with lower
diastolic pressures followed by large RSNA bursts. The inarguably dynamic nature of RSNA has
inspired investigators to use dynamic approaches to study the neural control of renal function.
One common dynamic method of analysis for studying rhythmic physiological time series
data is frequency analysis. This decomposes a physiologic signal occurring in time into its multiple
frequencies, allowing quantification of the power of each rhythm. Figure 19 shows how a
seemingly complex signal occurring in time can arise from a few simple rhythms and how
frequency analysis facilitates the identification and quantification of these rhythms. Frequency
analysis is a powerful tool for studying the control of physiological parameters as different
physiological control mechanisms operate at different frequencies. By separating physiological
mechanisms based on their operating frequencies, frequency analysis allows for their individual
assessment as they regulate the physiological parameter of interest in vivo. Contrast this with
classic, steady-state measures such as heart rate or renal vascular resistance which have no ability
to assess the contributions of individual physiological mechanisms working together to regulate the
parameter of interest. For example, if heart rate increases, one does not know if this is due to vagal
withdrawal or cardiac sympatho-excitation or both; if renal vascular resistance increases, one does
not know if this is mediated by sympathetic vasoconstriction, MR, or TGF. Frequency analysis
offers us a window into the participation of individual physiological control mechanisms – although
it is not without limitations.
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Figure 19 – Classic Frequency Analysis
A rhythmic signal which appears complex when viewed in time can be better understood after its transformation to the
frequency domain. The composite waveform on the left is the simple addition of three other oscillations of different
frequencies and amplitudes. When viewed in the frequency domain, the amplitude spectrum (right) reveals very clearly
the frequencies of the underlying rhythms and their relative contributions (amplitudes). The phase spectrum (not shown)
gives information about when each oscillation occurs (i.e. is at 0°).
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One of these limitations is that the frequencies of different physiological mechanisms may
overlap. Such is the case with heart rate: both parasympathetic and sympathetic inputs to the
sinoatrial node contribute to low-frequency (LF) oscillations in heart rate variability. Fortunately,
in the rabbit, rat, and mouse, the important dynamic controllers of the renal vasculature operate at
distinct frequencies. The important autoregulatory mechanism of TGF operates between 0.02-0.08
Hz while MR operates between 0.08-0.20 Hz126. In the rabbit, LF sympathetic vasomotion occurs
between 0.20 Hz to 0.46 Hz, and HF respiratory modulation occurs between 0.76 to 1.5 Hz135. If
some aspects of this terminology are confusing (e.g., the fact that the so-called LF range is the
second-highest frequency range), this is because we have united terminology from two different
fields, renal autoregulation and autonomic neurophysiology. The frequency ranges for TGF and
MR come from dynamic autoregulation studies, constituting what autonomic researchers
(particularly in the field of heart rate variability) nebulously call the very-low frequency range99.
The frequency ranges where LF sympathetic vasomotion and HF respiratory modulation occur
come from autonomic studies and are frequently ignored or combined in studies of renal
autoregulation.
Poiseuille’s Law tells us that the steady-state flow through a rigid tube is equal to the
perfusion pressure divided by the resistance of the tube. Thus, while the dynamic controllers of
renal vascular resistance are important, so, too, is renal perfusion pressure. In healthy animals, the
venous pressure is negligible, and thus AP can be used as a surrogate for perfusion pressure. This
powerful physical relationship between AP and RBF allows for the study of the dynamic control
of the renal vasculature.

Transfer Function Analysis of Renal Pressure-Flow
One way that the physical relationship between pressure and flow can be leveraged is by
using a classic system identification approach called transfer function analysis. Transfer function
analysis allows for the quantification of a dynamic input-output relationship, that is, an input-output
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relationship as a function of frequency. This introduction focuses on studies in which transfer
function analysis was used to identify the input-output relationship between AP and RBF for INV
and denervated (DNx) kidneys.
Multiple approaches exist for transfer function analysis, but the most common method, and
the one employed in all the studies reviewed here, is based on the Welch method of frequency
analysis. The basics of this method are important to understanding the results and avoiding the
pitfalls of this approach. The original arterial pressure and renal blood flow signals are divided into
several, overlapping time windows. Each time window is multiplied by a window function, which
reduces spurious edge effects caused by dividing the original signal into smaller time windows.
The Fast Fourier Transform (FFT) of each contemporaneous AP and RBF time window is
computed, converting the signals from the time domain to the frequency domain, where they are
referred to as spectra and have both real and imaginary components. The RBF spectrum and the
complex conjugate of the AP spectrum are multiplied to yield the cross-spectrum, which is then
normalized by the AP power spectrum (i.e. magnitude squared of the FFT). This is averaged across
all time windows to yield the final transfer function. Gain is calculated as the magnitude of the
transfer function as a function of frequency. Phase shift is calculated as the inverse tangent of the
imaginary and real parts of the transfer function for every frequency. Coherence is calculated by
squaring the magnitude of the transfer function and normalizing by the RBF power spectrum.
The Welch method of transfer function analysis is widely employed for several reasons.
First, averaging over multiple time windows greatly improves the signal-to-noise ratio; however,
there is an important tradeoff between signal-to-noise and frequency resolution. Increasing the
number of time windows accordingly decreases the length of each time window (e.g., deciding to
chop a 600-second recording into 6 non-overlapped 100-second windows instead of 3 nonoverlapped 200-second windows). This sacrifices frequency resolution as the frequency resolution
of the Welch method equals the reciprocal of the time window length (e.g., 0.01 Hz for a 100second window, 0.005 Hz for a 200-second window). As we show below, this tradeoff is important
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in resolving physiology. Second, calculating the transfer function over multiple time windows
allows one to assess the consistency of the linear input-output relationship over time, which is
quantified as coherence. Methods that do not use multiple time windows cannot compute this
physiologically significant measure.
When calculated carefully, the gain, phase shift, and coherence of the renal pressure-flow
relationship have distinct physiological meanings and show a clear role for the renal nerves in the
physiological control of RBF. However, it is important to understand that a one-size-fits-all
approach to the Welch method is inappropriate; the parameters of the analysis must be chosen
thoughtfully based on the physiological question at hand. We discuss herein the physiological
meanings of gain, phase shift, and coherence in the context of the renal pressure-flow relationship
and present what the contribution of the renal nerves to these three transfer function parameters
tells us about their role in normal physiological control of RBF. At the same time, we touch on
some signal processing issues which may explain discrepancies in the literature.
The data presented in the introduction come from rabbits that underwent either bilateral
renal denervation (DDNx) or a sham procedure (INV)53. These rabbits were chronically
instrumented with an AP telemeter and a RBF probe on the left renal artery. After a two-week
recovery and acclimation to the procedure room, AP and RBF were recorded, and AP-RBF transfer
function analysis was performed. We observed a clear sympathetic signature in the LF range where
sympathetic vasomotion is prominent. The specific phase shift, gain, and coherence of this LF
signature demonstrate how the renal nerves contribute to the physiological control of RBF.

86

Figure 20 – Time-Invariant Renal Pressure-Flow Gain
Representative AP and RBF oscillations depicting (A) buffering of AP oscillations by active renal
vascular control mechanisms resulting in negative admittance gain and (B) amplification of AP
oscillations by passive renal arterial elastance resulting in positive admittance gain. INV kidneys show
lower LF gain whether quantified as (C) raw gain, (D) fractional admittance gain, or (E) admittance gain.
(F) Erroneous normalization abolishes the ability of transfer function analysis to demonstrate physiology,
be it autoregulation or the contribution of the renal nerves.
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Renal Pressure-Flow Gain
Transfer function gain quantifies how much an AP oscillation at a given frequency affects
RBF. This is often normalized to the RVC, in which case it is called admittance gain and expressed
as a unitless quantity (often specified as fractional gain) or in decibels (dB). The idea of this
normalization is that it accounts for passive differences in the renal vasculature, thereby
emphasizing the dynamic contributions of the physiological control mechanisms. An admittance
gain less than 0 dB indicates that renal vascular control mechanisms are buffering the AP
oscillations relative to what would be expected from Poiseuille’s Law. Admittance gains greater
than 0 dB, indicative of amplified transduction of pressure into flow, are believed to result due to
the elastic nature of the renal artery.
From Figure 20B and C, one can appreciate that transfer function gain shows the strong
autoregulatory capacity of the kidney. Renal autoregulation results in low gain below the operating
frequencies of the autoregulatory mechanisms, highlighting the ability of these mechanisms to
effectively buffer slow AP oscillations.
Measures of AP-RBF gain reveal that the renal nerves buffer the transduction of LF AP
oscillations into RBF, whether calculated as raw gain, fractional admittance gain, or admittance
gain in dB (Figure 20C-E). Other studies in the chronically denervated, conscious rabbit and acutely
denervated, anesthetized rat have similarly shown that renal denervation increases raw gain and
admittance gain, respectively, beyond the autoregulatory frequency range116,136. Thus, in both rats
and rabbits, sympathetic control of RVC attenuates the effect of LF AP oscillations on RBF,
consistent with a dynamic vasoconstrictive influence.
One notable study, however, failed to find an increase in admittance gain after acute renal
denervation of healthy, anesthetized rats137. This may be due to how the admittance gain was
normalized in this study. The authors performed mean subtraction, which eliminates the 0-Hz
component, and then proceeded to normalize transfer function gain for all frequencies by the
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calculated transfer function gain at 0 Hz. This is analogous to dividing by zero. Figure 20F shows
the effect of such a procedure on our data. The erroneous normalization yields implausible data
(e.g., admittance gain > 0 dB for all frequencies), and the effect of renal denervation on gain is
completely abolished. This demonstrates an important point: valid signal processing is important
for accurate descriptions of physiology.

Figure 21 – Time-Invariant Renal Pressure-Flow Phase Shift
Representative depictions of (A) AP oscillations leading RBF oscillations as would be expected for an
active control system sensing AP and modulating RVC (e.g., baroreflex) and (B) RBF oscillations
leading AP oscillations as would be expected for an active control system sensing RBF and modulating
RVC (e.g., autoregulation). (C) INV kidneys show a negative phase shift in the LF range which is
abolished by renal denervation. (D) This difference is masked when longer time windows, which result
in greater frequency resolution but poorer signal-to-noise, are used.
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Renal Pressure-Flow Phase Shift
The AP-RBF transfer function phase shift quantifies when RBF oscillations relative to AP
oscillations. If an AP oscillation occurs after an RBF oscillation, the phase shift is negative (Figure
21A). If an AP oscillation occurs before an RBF oscillation, the phase shift is positive (Figure 21B).
Phase shift may be expressed as radians, in which case it is bounded between -π and +π, or degrees,
in which case it is bounded between -180 and 180, as one cannot distinguish between oscillations
leading or lagging by more than one half-phase. The time lag between AP and RBF oscillations
can be calculated as the product of the phase shift and the period of the oscillation of interest. If AP
and RBF are synchronized (as depicted in Figure 20A and B), the phase shift is zero; this is the
case for passive pressure-flow. When non-zero, phase shift also conveys important information
about causality in a Granger sense (i.e. the cause occurs before the effect). Thus, when AP-RBF
phase shift is positive, RBF oscillations precede AP oscillations, indicating the presence of an
active control system which modulates RVC in response to RBF oscillations. Conversely, when
AP-RBF phase shift is negative, AP oscillations precede RBF oscillations, indicating the presence
of an active control system which modulates RVC in response to AP oscillations. While zero phase
shift is characteristic of passive, Poiseuille flow, it can also arise from an AP-independent active
control system (e.g., RSNA not under baroreflex control) which will contribute phase asynchrony,
decreasing AP-RBF coherence despite the zero phase shift.
The contribution of sympathetic control to the renal pressure-flow phase shift can be
appreciated in Figure 21. INV rabbits show a negative phase shift in the LF range, characteristic of
baroreflex control of RVC. Renal denervation abolishes this negative phase shift, and instead the
DDNx phase shift simply decays to zero, characteristic of passive pressure-flow. This matches well
with the previous observation that resting RSNA is under strong baroreflex control (Figure 18).
Interestingly, while our study was the first to report this effect as statistically significant, a clear
trend for renal denervation to increase LF phase shift can be seen in studies in the conscious rabbit

90
and acutely denervated anesthetized rat116,136. The difference may arise from the signal processing
parameters used in these studies, which were targeted at resolving autoregulatory frequency ranges.
When we use similar parameters, increasing window length to 200 seconds and thereby decreasing
the number of time windows, the noise in the LF range increases greatly and the effect of renal
denervation is masked (Figure 21D).
Of course, variations in underlying RSNA are also undoubtedly important as RSNA which
is not under baroreflex control may contribute to phase asynchrony instead of a negative phase
shift. Further emphasizing this idea are reports that a negative AP-RBF phase shift is frequently
observed but only in a subset of recordings (~1 in 7) from INV rats 138. Because of the importance
of the murine model, it is worth noting that a negative phase shift is also seen in the LF range of
conscious, INV mice139. The fact that the renal vasculature is under sympathetic baroreflex control
indicates that the renal nerves modulate RVC as part of a concerted systemic mechanism for
modulating total peripheral resistance to maintain AP, not a local reflex which autoregulates RBF.
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Renal Pressure-Flow Coherence
Strictly speaking, coherence measures the proportion of the variance in AP oscillations that
is explained by a linear relationship with AP oscillations for all the time windows in the recording.
Thus, coherence is a measure of the strength of the linear, time-invariant relationship between AP
and RBF at a given frequency. Put more plainly, coherence is a quantification of how consistently
linear the pressure-flow relationship is over time; it’s the transfer function analog of the correlation
coefficient and similarly ranges from zero to one. Figure 22A depicts an example of high coherence;
the RBF oscillation follows the AP oscillation perfectly, amplifying the AP oscillation by 20% and
lagging by a quarter phase. Figure 22B depicts low coherence; in this case, the RBF oscillation is
a time-varying, nonlinear function of the AP oscillation.
Frequently, coherence is used as a quality control method, with a cut-off of 0.5 applied to
determine whether the physiological control mechanism (e.g., TGF, MR) is effectively
characterized by the estimated transfer function. Unfortunately, this is not an appropriate
interpretation of coherence as the calculated coherence is not a characteristic, invariant quantity of
the AP-RBF system or even of the individual recording; instead, it depends highly on the
parameters used for the Welch method. To illustrate this point, we have calculated coherence for
AP and RBF from INV rabbits, varying only the parameters of the Welch method. Specifically,
50%-overlapping windows of 50, 100, 200, 300, 400, and 600 seconds were used to yield 23, 11,
5, 3, 2, and 1 window for analysis. As one can see in Figure 22C and D, as the number of windows
decreases, the coherence in the presence of active control mechanisms (i.e. in TGF, MR, and LF
range) increases greatly. Obviously, the underlying physiological system has not changed, nor has
the quality of the data, and, in a statistical sense, the lower coherence values with greater window
number are offset by the increase in the degrees of freedom. It should be noted that although
coherence can be calculated using less than three independent (i.e. non-overlapping) windows,
calculations of coherence performed in this way are invalid.
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Figure 22 – Time-Invariant Renal Pressure-Flow Coherence
Representative depictions of (A) a RBF oscillation with high coherence to the AP oscillation and (B) a
RBF oscillation with low coherence to the AP oscillation. (C) Coherence depends on signal processing
parameters and decreases with increasing number of windows. (D) Mean coherence over frequency
bands for TGF, MR, LF, and HF, demonstrating the sensitivity of coherence to signal processing
parameters. (E) Renal denervation selectively increases AP-RBF coherence in the LF range.
nwin, number of 50% overlapping windows used for Welch method
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Despite this misunderstanding, coherence provides immensely important insight into the
renal-pressure flow relationship. In the absence of active modulation of RVC, the conditions for
Poiseuille flow are well-met below the cardiac frequency, ensuring a linear pressure-flow
relationship. Thus, any departures from the linear relationship between pressure and flow are
indicative of active modulation of RVC. In other words, pressure-flow coherence is low in the
presence of active control mechanisms (i.e. where pressure is not the only determinant of flow) and
high where a passive pressure-flow relationship predominates. Accordingly, we urge the reader to
consider AP-RBF coherence as accurate only when the calculated coherence is low in the
autoregulatory frequency range and high in the high frequency (respiratory) range. In the absence
of interventions which inhibit autoregulation, high coherence in the autoregulatory frequencies is
highly indicative of incorrectly calculated coherence; low coherence in the respiratory frequency
range may indicate poor data quality. The literature is unfortunately full of such examples.
With this understanding of coherence, the fact that the renal nerves contribute to the active
control of RBF can be appreciated from Figure Figure 22E. In INV kidneys, AP-RBF coherence is
low for the TGF, MR, and LF ranges, increasing rapidly to a passive maximum in the HF range.
Renal denervation eliminates this LF active controller, and the coherence instead increases to the
passive maximum over the LF range. This indicates that the renal nerves mediate active control of
renal pressure-flow in the LF range. The other study which reports AP-RBF coherence similarly
found that renal denervation increases coherence beyond the autoregulatory frequencies, again
emphasizing that the renal nerves are an important contributor to the rapid control of RBF116.

Summary of the Sympathetic Regulation of Renal Pressure-Flow
In summary, the renal sympathetic control buffers the transduction of LF AP oscillations
to RBF, exerts LF baroreflex control over RVC, and decreases LF renal-pressure flow coherence.
The integration of these three findings is important to fully understand renal sympathetic vascular
control. It may seem counterintuitive that a baroreflex controller of pressure-flow would decrease
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pressure-flow gain; indeed, some have stated that a baroreflex controller would increase pressureflow gain (although all experimental evidence has shown the opposite to be true). Consider the case
where AP rises above the set point, initiating a baroreflex-mediated decrease in total vascular
conductance. A decrease in RVC in response to increased AP would result in amplification of AP
oscillations and thus high AP-RBF gain.
In reality, this is not what happens because the sympathetic nervous system relies
predominantly on α1-adrenergic-mediated vasoconstriction to modulate total peripheral
conductance and RVC. Thus, to be able to respond to both increases and decreases in AP, the
sympathetic nervous system must provide some basal level of systemic vasoconstriction. This
rhythmic sympathetic vasoconstriction gives rise to LF AP oscillations known as the Mayer waves,
which are minor and variable in an unstressed, healthy animal but increase manifold when strong
hemodynamic

stimuli

like

hemorrhage

and

hypoxia

drive

global

LF

sympathetic

synchronization140. It is this rhythmic vasoconstriction which explains the decreased AP-RBF LF
gain in INV kidneys. In response to an increase in pressure, this rhythmic vasoconstriction is
withdrawn, contributing to the baroreflex-mediated increase in total vascular conductance and
resulting in a relative elevation in AP-RBF gain. In the case that the nerves are completely silenced
by the increase in AP, the AP-RBF gain in the LF range will reach passive AP-RBF gain.
This same variability in the underlying RSNA explains the decreased LF coherence
observed in INV rabbits that is restored by renal denervation. The sympathetic rhythms generating
renal sympathetic vasomotion, sometimes participating in the generation of LF AP oscillations and
other times responding to them, sometimes exerting strong vasoconstriction in response to
decreased AP and going quiescent in response to increased AP, decrease the consistency of the APRBF relationship. Moreover, the fact that RSNA can be entrained by other reflexes including the
central/peripheral chemoreceptor reflexes, cardiopulmonary baroreflex, and the cardiac
sympathetic afferent reflex, further contributes to the variability in the AP-RBF relationship.
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Figure 23 – Time-Frequency Analysis
Time-frequency analysis allows for the estimation of spectral energy localized in time. Performing a
wavelet transform with multiple scales results in a three-dimensional plot with the square-magnitude of
the spectral energy for each frequency encoded as color, with yellow being high energy and blue being
low energy. The black lines indicate the border of the edge-affected time points; everything outside these
lines is affected by edges because the time series isn’t infinite and should be ignored.
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Time-Varying Transfer Function Analysis of Renal Pressure-Flow
We have shown that optimal signal processing is crucial in order to accurately characterize
the underlying physiology of the renal pressure-flow system, and, while the Welch method has
several advantages in terms of signal-to-noise ratio, it also has a marked disadvantage: all
information on when oscillations occur is lost. Time-frequency analysis allows for the variance (i.e.
power) of a signal to be localized in both time and frequency. This results in a three-dimensional
(3D) plot in which the distribution of the signal variance is displayed as spectral energy in timefrequency space (Figure 23). As the previous section describes, different entrainment of underlying
RSNA may explain disparate results in previous studies of renal pressure-flow. For example, LF
baroreflex behavior may be visible in an INV kidney but only for a portion of the recording, which
will be lost as multiple windows are averaged together. Thus, using time-frequency analysis to
create a time-varying renal pressure-flow transfer function may allow for characterization not only
of the predominant behavior at each frequency but also the distribution of the pressure-flow transfer
function behavior over time.
While one can find many examples of time-frequency analysis applied to cardiovascular
variability in the literature, one reason why it the technique remains much less popular than
frequency analysis is because it is difficult to leverage the additional data for across-time
comparisons. For example, during a baseline recording, there is little rationale to compare a 0.3 Hz
oscillation occurring 2.5 minutes after the beginning of one recording to a 0.3 Hz oscillation
occurring 2.5 minutes after the beginning of a different recording. Thus, when time-frequency
analysis is performed, the measures are often simply averaged over time, largely defeating the
purpose of time-frequency analysis and yielding a result very similar to that obtained by the Welch
method.
One approach to this issue is to leverage the fact that there are two kidneys by denervating
one and leaving the nerves in-tact contralaterally. Now, both time and perfusion pressure are
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directly comparable for an INV and a DNx kidney, facilitating powerful comparisons and
eliminating many potential confounds. Between-subjects comparisons can also be facilitated using
occurrence histograms, with time that the INV and DNx kidney spend between certain values of
admittance gain, phase shift, and coherence values calculated and compared.

Hypothesis
We hypothesized that time-varying transfer function analysis of unilaterally denervated
rabbits instrumented with bilateral renal flow probes would elegantly demonstrate LF renal
sympathetic vasomotion in the INV kidney and passive pressure-flow in the DNx kidney.

Methods
Animals
Experiments were carried out on male New Zealand White rabbits ranging in weight from
3.2 to 4.5 kg (Charles River Laboratories, International, Wilmington, MA). All experiments were
reviewed and approved by the University of Nebraska Medical Center Institutional Animal Care
and Use Committee and carried out in accordance with the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. Rabbits were housed in individual cages
in a temperature-controlled room (23º C) with a 12:12 hour light-dark cycle (lights on at 07:00,
lights off at 19:00). Rabbits were given ad libitum access to reverse-osmosis purified water and
high-fiber rabbit chow (Teklad 2031, Envigo RMS, Indianapolis, IN).

Instrumentation
Each rabbit was instrumented with an AP telemetry and bilateral renal flow probes. After
induction with ketamine and xylazine and under isoflurane anesthesia and positive pressure
ventilation, a radiotelemetry device was implanted in the right femoral artery in order to record AP.
This was done by performing a femoral cut-down and threading a catheter attached to a
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radiotelemetry transducer (PA-C40, Data Sciences International, St. Paul, MN) into the abdominal
aorta. Rabbits then underwent bilateral renal flow probe instrumentation with unilateral renal
denervation. The kidney to be denervated was randomized (randomization seed #19423 from
randomization.com was used). During this surgery, bilateral flank incisions were made, and the
renal arteries and veins were carefully dissected using glass rods. The kidney randomized to be
denervated had its artery stripped of all visible neural tissue. A 2-mm renal flow probe (Transonics
Systems, Inc., Ithaca, NY) was secured around both renal arteries using a piece of Silastic sheeting
and 4-0 silk suture. The probe cable was tunneled beneath the skin and exited in the midscapular
region of the rabbit. After each surgery, rabbits received a single dose of buprenorphine (0.02 mg/kg
subcutaneously), a three-day course of antibiotics (Baytril, 22.7 mg/day subcutaneously, Bayer
Health Care, Shawnee Mission, KS) and three days of pain control via a transdermal patch
(fentanyl, 25µg/hr, Mylan Pharmaceuticals, Morgantown, WV). Prior to data collection, rabbits
recovered for at least 14 days.

Acclimation
Prior to data collection, rabbits were acclimated to the experimental procedure room and
Plexiglass experiment box. The rabbits were handled daily until signs of stress were absent and
rabbits were accustomed to resting calmly in the experiment box in the procedure room. This
involved a minimum of five, 1-hour procedure room acclimation sessions.

Baseline Recordings
After this acclimation period, rabbits underwent data collection for subsequent analysis.
AP and bilateral RBF were digitized at 1 kHz via a PowerLab system (AD Instruments, Colorado
Springs, CO) for at least 1 hour. This recording was used to validate that the rabbit's instrumentation
is functioning properly. Rabbits were to be excluded if their baseline hemodynamics assessed by
their instrumentation failed to meet basic inclusion criteria. These criteria were pre-defined in an
Open Science Framework pre-registration which will be released from embargo when the study is
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published in manuscript form. In one case, a rabbit was excluded as he had chewed off one of his
flow probes.

Nasopharyngeal Reflex
At the end of this data collection, the nasopharyngeal reflex was invoked. Cigarette smoke
was drawn through its filter into a 60 mL syringe so that the entire syringe is opaque with smoke.
The smoke was then gently delivered to the rabbit's face over 10 seconds, resulting in near maximal
autonomic activation. This renal vasoconstrictive response was used to validate completeness of
denervation and to ensure that the intact kidney is indeed innervated. Rabbits were excluded if the
RVC of the DNx kidney decreases >30% or if the RBF of the INV kidney remained >1 mL/min.
The INV kidney of one rabbit failed to decrease below 15 mL/min, indicating significant partial
denervation during renal flow probe implantation, and this rabbit was excluded from analysis.
These exclusion criteria were pre-defined in an Open Science Framework pre-registration which
will be released from embargo when the study is published in manuscript form.

Euthanasia
Before sacrifice and tissue collection, the rabbits were anesthetized with ketamine (35
mg/kg) and xylazine (5.8 mg/kg) intramuscular injection. After local infiltrations of bupivicaine, a
right femoral cutdown was performed, and the left femoral artery was cannulated with a Millar
pressure transducer. The difference between the chronically implanted telemetry and the acutely
introduced transducer was used to calibrate AP from the previously collected conscious data.
Kidneys were collected for molecular validation of denervation.

Analysis
Artifact-free, 10-minute segments from these recordings were used to perform all
subsequent analysis. All sections of data were relatively stationary with regard to AP, right and left
RBF, and HR. Prior to data analysis by Peter Ricci Pellegrino, the data was blinded by Alicia Marie

100
Schiller. This was accomplished by saving a de-identified data file without the data segment
containing the nasopharyngeal reflex. Data analysis was performed as follows.
In order to eliminate time delays, the bilateral RBF signals were synchronized to AP using
the maximum of the cross-correlation. Pulse onsets were detected using the maximum of the 2nd
derivative of the AP signal and manually screened for artifacts. Pulsatile AP and bilateral RBF
signals were averaged over each pulse, yielding beat-to-beat data used for analysis. Mean
hemodynamic parameters, including HR, mean AP, left and right mean RBF, and left and right
mean RVC were calculated from this beat-to-beat data.
Time-varying transfer function analysis was performed using MATLAB (MathWorks,
Inc., Natick, MA). The beat-to-beat data were linearly interpolated at 5.12 Hz. Time-frequency
analysis of each signal was performed using a continuous complex Morlet wavelet with scales
calculated to yield 251 pseudofrequencies ranging from 0.02 Hz and 1.5 Hz that are linearly spaced
when plotted logarithmically. Pseudofrequencies were grouped into bands based on previous
studies in rabbits which have shown that TGF operates between 0.02-0.08 Hz, the myogenic
response operates between 0.08-0.20 Hz, the LF band where sympathetic vasomotion gives rise to
the so-called Mayer waves ranges from 0.20-0.45 Hz, and the HF band encompassing the
respiratory frequency ranges from 0.75-1.5 Hz. The linear, time-varying transfer function was
calculated for each kidney by computing the AP-RBF cross-spectrum and normalizing by the
square of the AP spectral energy for every pseudofrequency and every time point. Gain is the
amplitude of this time-varying transfer function; phase shift is the angle of the real and imaginary
components (i.e. the inverse tangent of the quotient of the imaginary component divided by the real
component of the time-varying transfer function). Admittance gain in decibels was calculated by
normalizing the gain by RVC, computing the base-10 logarithm of this normalized gain, and
multiplying this logarithm by 20. Standard time-varying coherence will use smoothing window
lengths that yield three independent oscillations for each pseudofrequency (i.e. three divided by the
pseudofrequency). Points in the time-pseudofrequency space influenced by edge effects were
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excluded from analysis. Phase shift, admittance gain, and coherence time variability were
calculated as both the standard deviation and interquartile range for each pseudofrequency over the
course of the recording. Occurrence plots of phase shift, admittance gain, and coherence were
calculated.
These parameters were calculated for each recording and visualized by Peter Ricci
Pellegrino before unblinding of the data by Alicia Marie Schiller.
Null hypothesis testing will be performed after unblinding of the second group of rabbits
which has not yet been completed. This will be performed by RM-ANOVA with GreenhouseGeisser corrections for sphericity with P values < 0.05 considered statistically significant. Because
much of the occurrence data described is best visualized as a heat map (3D plot), the data is
presented as mean data for innervated and denervated kidneys with t-statistics and P values
computed for each point in the x-y space in order to convey directionality, magnitude, and
consistency of innervated/denervated renal pressure-flow differences. These P values are
descriptive only and are not intended to convey statistical significance per se.
Additional testing will be performed for data averaged across frequency bands. When the
RM-ANOVA for data averaged across frequency bands shows a statistically significant effect of
renal innervation, paired t-tests will be performed between INV and DNx for each frequency band.
These paired t-tests will be one-tailed (H0: DNx < INV for measures of variability, H0: DNx >
INV for measures of coherence), and a Sidak correction for multiple comparisons will be applied
to the standard alpha = 0.05 (i.e., with 4 frequency bands, the critical P value = 0.01274). Even
when the RM-ANOVA for data averaged across frequency bands does not show a significant effect
of renal innervation, the LF band, where sympathetic vasomotion is prominent, will be tested for
differences using a paired, two-tailed t-test between INV and DNx with alpha = 0.05.
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Table 12 – Mean Measures of Basal Hemodynamics for Unilaterally Denervated Rabbits
Hemodynamic Measure
AP (mm Hg)

80.1 ± 3.3

INV RBF (mL/min)

39.8 ± 5.3

DNx RBF (mL/min
HR

47.3 ± 3.0
212 ± 9

INV RBF
(mL/min)

DNx
RBF
(mL/min)

AP
(mm Hg)

Values are displayed as mean ± SEM.
n=5

Figure 24 – Representative Tracing of the Nasopharyngeal Reflex
The robust autonomic activation elicited by the nasopharyngeal reflex (dotted line) results in a robust bradycardia
(visible best in AP and DNx RBF) and near-maximal renal sympathetic vasoconstriction. DNx RBF is unchanged
while INV RBF goes to zero.
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Results
Mean Measures of Baseline Hemodynamics
Baseline means for AP, RBF to the INV kidney, RBF to the DNx kidney, and HR are
shown in Table 12. Importantly, the difference between INV and DNx RBF was not statistically
significant (PSx = 0.30).

Nasopharyngeal Reflex
Elicitation of the nasopharyngeal reflex results in a large parasympathetic and sympathetic
activation. This sympathetic activation drives RBF in the INV kidney below 1 mL/min while the
RBF to the DNx kidney remains relatively unchanged (Figure 23). This response was used to
functionally validate innervation status of the kidney. The RBF of the INV kidney of one rabbit
failed to fall below 15 mL/min despite multiple attempts on different days, indicating partial
denervation of the kidney during RBF probe implant. Per the pre-registered exclusion criteria, this
rabbit was excluded from all subsequent analysis.
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Figure 25 – Representative Time-Varying AP-RBF Admittance Gain Plots
Representative time-varying admittance gain plots are shown for the pressure-flow to an (A) INV kidney and (B) DNx
kidney in the same rabbit. Focusing on the LF and HF ranges, the (C) INV kidney shows blue LF vasoconstriction which is
absent in the (D) DNx kidney. Black contour lines were added to emphasize the LF variability (i.e. vasomotion) effected by
the renal nerves and absent after denervation. Also appreciate the exquisite similarity in the HF range by virtue of their
identical perfusion pressure and predominance of passive pressure-flow in this frequency range.

105

A

B

C

D

Figure 26 – Sympathetic Signature in AP-RBF Admittance Gain Behavior
Mean AP-RBF admittance gain occurrence for bins of with 5 dB for (A) INV and (B) DNx kidneys. (C) T-statistics
and (D) P values indicate a specific sympathetic signature resulting in low gain occurrence in the LF range, consistent
with a rapid, vasoconstrictive influence which is eliminated by denervation. n = 5

Time-Varying Renal Pressure-Flow Admittance Gain
A representative tracing of the admittance gain reveals a time-varying, vasoconstrictive
influence in the LF range of the INV kidney that is absent in the DNx kidney (Figure 25). A similar
effect was seen in all INV kidneys but never in DNx kidneys (Figure 26). Thus, this fast
vasoconstriction is a part of a specific renal sympathetic pressure-flow signature. Moreover, the
increased LF variability over time, while visible in Figure 25 and Figure 26, is explicitly quantified
in Figure 27. Whether quantified as the standard deviation or interquartile range for each frequency
over time, INV kidneys have higher LF admittance gain variability than their DNx counterparts
despite the exact same perfusion pressure. In summary, time-varying renal pressure-flow
admittance shows clearly that the renal nerves exert a time-varying rhythmic vasoconstrictive
influence in healthy, conscious rabbits. This provides strong evidence that renal sympathetic
vasomotion is a physiological phenomenon.
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Figure 27 – Renal Pressure-Flow Admittance Gain Time-Variability
Whether calculated as (A) standard deviation or (B) interquartile range, admittance gain time-variability is higher for
INV kidneys compared to DNx kidneys, indicating that the renal nerves exert time-varying modulation of renal
vascular tone. SD, standard deviation; IQR, interquartile range; |G|, admittance gain
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Figure 28 – Representative Time-Varying AP-RBF Phase Shift Plots
Representative time-varying phase shift plots are shown for the pressure-flow to an (A) INV kidney and (B) DNx kidney
in the same rabbit. Focusing on the LF and HF ranges, the (C) INV kidney shows blue baroreflex control which is absent
in the (D) DNx kidney. Black contour lines were added to emphasize the LF variability (i.e. vasomotion) effected by the
renal nerves and absent after denervation. Also appreciate the exquisite similarity in the HF range by virtue of their
identical perfusion pressure and the predominance of passive pressure-flow in this frequency range.
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Time-Varying Renal Pressure-Flow Phase Shift
A representative tracing of the pressure-flow phase shift reveals a time-varying, baroreflex
influence in the LF range of the INV kidney which is absent in the DNx kidney (Figure 28).
Interestingly, all INV kidneys showed increased phase asynchrony (i.e. phase shift ≠ 0) but not all
showed a clear baroreflex predominance as was shown in the prior data set from unilaterally
instrumented INV rabbits (Figure 29). This indicates that, while there is a strong role for the arterial
baroreflex in sympathetic control of RBF, other AP-independent sympathetic rhythms are also
important effectors of renal sympathetic vasomotion. As for admittance gain, measures of pressureflow phase shift time-variability are elevated for the INV kidney compared to the DNx kidney,
providing further evidence for the importance of the time-varying approach to pressure-flow
analysis when attempting to understand inherently time-varying physiological phenomena (Figure
30).
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Figure 29 – Sympathetic Signature in AP-RBF Phase Shift Behavior
Mean AP-RBF phase shift occurrence for bins of width π/10 for (A) INV and (B) DNx kidneys. (C) T-statistics and
(D) P values indicate a specific sympathetic signature resulting in phase asynchrony in the LF range, consistent with
an active, asynchronous vascular control mechanism which is eliminated by denervation. n = 5
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Figure 30 – Renal Pressure-Flow Phase Shift Time-Variability
Whether calculated as (A) standard deviation or (B) interquartile range, pressure-flow phase shift time-variability is
higher for INV kidneys compared to DNx kidneys, indicating that the renal nerves exert time-varying modulation of
renal vascular tone. SD, standard deviation; IQR, interquartile range; ϕ, admittance gain
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Figure 31 – Representative Time-Varying AP-RBF Coherence Plots
Representative time-varying coherence plots are shown for the pressure-flow to an (A) INV kidney and (B) DNx kidney
in the same rabbit. Focusing on the LF and HF ranges, the (C) INV kidney shows green-blue vasomotion which is absent
in the (D) DNx kidney, which exhibits blinding yellow passive pressure-flow.
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Figure 32 – Sympathetic Signature in AP-RBF Coherence Behavior
Mean AP-RBF coherence occurrence for bins of width 0.05 for (A) INV and (B) DNx kidneys. (C) T-statistics and (D) P values
indicate a specific sympathetic signature resulting in low coherence in the LF range, consistent with a fast, active control
mechanism which is eliminated by denervation. n = 5
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Time-Varying Renal Pressure-Flow Coherence
A representative tracing of the pressure-flow coherence reveals low coherence in the LF
range of the INV kidney which is absent in the DNx kidney, indicating the action of a vascular
control mechanism in INV kidneys which is eliminated by renal denervation (Figure 31). Low LF
pressure-flow coherence was seen in all INV kidneys but absent in DNx kidneys (Figure 32),
indicating that LF renal sympathetic vasomotion is a fundamental part of physiological renal
vascular control.

Occurrence in 3D Pressure-Flow Space
While it is meaningful to look at renal pressure-flow admittance gain, phase shift, and
coherence in isolation because of their distinct physiological meanings, it is important to remember
that each point in time has a gain, phase shift, and coherence value. This multidimensional system
is difficult to visualize, but one method for visualization of this system for 0.3 Hz oscillations,
located firmly in the LF range, is shown in Figure 33. This shows the ratio of DNx occurrence to
INV occurrence for 0.3 Hz oscillations in pressure-flow in a 3D space of admittance gain, phase
shift, and coherence. The opacity of the points represents the sum of the mean occurrence for both
INV and DNx, so points with little to no occurrence are transparent. When visualized this way, one
can appreciate the wide ranging behavior of the INV kidney, whose pressure-flow relationship is
driven across this space by renal sympathetic vasomotion. This contrasts to the focal, passive
behavior of the DNx kidney, which exclusively shows high-gain, synchronous, and high-coherence
pressure-flow at 0.3 Hz.
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Figure 33 – INV and DNx 0.3 Hz Occurrence in 3D Pressure-Flow Transfer Function Space
The ratio of the mean DNx occurrence in a 3D transfer function space relative to the mean INV occurrence for 0.3 Hz
oscillations. The sum mean occurrence is encoded as opacity while yellow indicates higher DNx occurrence and blue
indicates higher INV occurrence. showing a predominance of high-gain, synchronous, high-coherence pressure-flow
in DNx kidneys and more variable, low-gain, asynchronous, low-coherence pressure-flow in INV kidneys.
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Discussion
This well-controlled study in unilaterally innervated rabbits with bilateral renal flow probes
shows clearly that the renal nerves contribute to the physiological control of RBF. Sympathetic
control of the renal vasculature imparts a time-varying vasoconstrictive influence which allows for
the modulation of RVC as part of a concerted systemic response to hemodynamic stimuli whether
they are small, physiological stimuli like postural changes, activity, and minor AP disturbances or
large experimental stimuli like the nasopharyngeal reflex, hypoxia, or hemorrhage. This shows that
the renal circulation is under strong sympathetic control like many other vascular beds and begs
the question: How has the dogma to the contrary persisted for so long? We propose that the putative
non-physiological, non-linear relationship between sympathetic outflow and RBF is simply the
manifestation of the failure to consider the confounding influence of powerful renal autoregulatory
mechanisms, and we encourage investigators not to forget about TGF and MR when interpreting
experiments involving the control of RBF.
Studies performing dynamic electrical stimulation of the renal sympathetic nerves, either
by sine wave or pseudorandom binary sequences, are particularly relevant to the discussion of the
relationship between the underlying renal sympathetic nerve activity and the resultant renal
vasomotion141–143. These studies indicate that the renal vasculature works as a low-pass filter,
effectively eliminating sympathetic rhythms in the HF range. This explains why RSNA power at
the respiratory and cardiac cycle frequencies does not reduce AP-RBF coherence; it is filtered by
the vasculature.
Other convincing studies show how the renal nerves play a role in RBF control during
normal activities. Chronically instrumented rats while grooming or sleeping show simultaneous
increases in RSNA and decreases in RBF144. During brief, episodic activity, unilaterally denervated
rabbits instrumented with bilateral renal flow probes showed increased variability in the episode-
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averaged RBF and the AP-RBF relationship131. These studies clearly show that rapid, physiological
changes in sympathetic outflow influence RBF.
Still other studies have used dynamic approaches to examine the response to experimental
stimuli like hypoxia and hemorrhage115,116. These studies have shown an important role for the renal
nerves in the generation of LF RBF oscillations in these sympatho-excitatory conditions and are
reviewed more comprehensively elsewhere140.
The techniques employed in this chapter to identify and characterize sympathetic
vasomotion have several applications beyond the study of physiology. The most immediate clinical
application pertains to the burgeoning field of renal denervation, that is, the use of a minimally
invasive medical device to remove the renal sympathetic nerves. Presently, therapeutic renal
denervation has significant momentum among clinicians and in the medical device industry. After
promising Phase I and Phase II results showing large blood pressure reductions in hypertensive
patients after renal denervation, the Phase III trial using the Medtronic catheter failed to lower blood
pressure compared to a sham procedure145. Post-hoc analysis and expert opinion implicate
inadequate renal nerve removal as the main reason for this shortcoming146,147. At present, none of
the renal denervation systems provide the interventionist with any feedback about the success of
the renal denervation. Because removal of the sympathetic nerves abolishes sympathetic
vasomotion, this technology could allow for intraoperative validation of renal denervation,
increasing the success of the procedure. It could also be used longitudinally to monitor patients to
assess regrowth of the renal nerves or prognostically to identify treatment responders. It may also
help companies to demonstrate device superiority or non-inferiority without the need to conduct
expensive and challenging sham-controlled efficacy trials.
Other potential applications for this technique pertain to chronic, progressive diseases
involving the sympathetic nervous system. Many diseases, including multiple systems atrophy,
Parkinson’s disease, diabetes, and pure autonomic failure can result in sympathetic failure and
syncope. Clinical testing of the sympathetic nervous system is a mainstay in the work-up of patients
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with clinical indications of sympathetic failure, but current autonomic tests are so crude,
insensitive, and poorly reproducible that their use is discouraged in the context of syncope148. Our
technique is inherently quantitative and allows for assessment of regional sympathetic vasomotor
function. This means that this technique could be used clinically to diagnose sympathetic failure,
map disease localization, assess disease severity, track progression of disease over time, and to
evaluate or predict a patient’s response to a therapy. By contrast, in cardiovascular and renal
disease, excessive sympathetic activity contributes to disease progression and mortality. At present,
no clinically useful test exists for the assessment of sympathetic activity. The introduction of a
clinical tool for measuring regional sympathetic vasomotion could be used to better stratify
patients, track disease progression, and guide treatment decisions.
In summary, the results of this study refute the idea that the renal sympathetic nerves do
not contribute to physiological RBF control. The evidence for this dogma derives from historical
interpretations which overlook both the role of the renal nerves and the strength of renal
autoregulation. Careful dynamic analysis of the in-tact and denervated renal pressure-flow system
reveals a clear role for the renal nerves as physiological regulators of RBF, operating on a beat-tobeat basis to recruit the renal vasculature according to underlying sympathetic rhythms.
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Conclusions
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Major Findings of the Dissertation
The major findings of the dissertation are:
1. That the pressor, sympatho-excitatory, and baroreflex dysfunction caused by central AngII
depend on Rho kinase activation (Chapter I).
2. That pulse rate variability is a generally acceptable surrogate for heart rate variability for timeand frequency-domain measures, but the additional contribution of respiration to and the
differing nonlinear properties of pulse rate variability should be considered by investigators
(Chapter II).
3. Physiological renal sympathetic vasomotion can be detected, visualized, and comprehensively
characterized using time-varying transfer function analysis of renal pressure-flow (Chapter III).
This work spans from the molecular mechanisms underlying sympatho-excitation in
cardiovascular disease to validating widely used techniques for cardiac autonomic assessment to
the development and application of a new method of detecting sympathetic vasomotion. Each of
the major findings is discussed individually and then together in the context of my training as an
aspiring physician-scientist.
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Main Finding I: The Autonomic Effects of Central AngII Depend on Rho
Kinase
Activation of the RAAS and autonomic dysfunction are pathophysiological hallmarks of
cardiovascular disease. Our data shows that the pro-hypertensive, sympatho-excitatory, and
baroreflex-perturbing effects of AngII in the brain are mediated by Rho kinase activation (Figure
34). This included direct recordings of sympathetic nerve activity, which showed that Rho kinase
inhibition prevents the chronic renal sympatho-excitation and baroreflex dysfunction caused by
central angiotensin. These data indicate that inhibition of the central Rho kinase pathway may act
as a therapeutic brake on the positive feedback between central RAAS activation and sympathetic
outflow in many diseases characterized by sympatho-excitation. Statins reduce Rho kinase
activity and sympathetic outflow, and this study suggests that Rho kinase inhibition may be an
important LDL-independent protective mechanism for the >30 million Americans currently
taking statins.
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Figure 34 – Summary Figure of Main Finding I
Central AngII activates Rho kinase signaling downstream of AT1R, leading to baroreflex dysfunction,
sympatho-excitation, and hypertension.
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Main Finding II: Invasive Pulse Rate Variability as a Surrogate for Heart
Rate Variability
HRV is the main determinant of invasively acquired PRV, and thus, it is an accurate and
precise surrogate for time, frequency, and some non-linear measures of HRV at baseline. PRV
slightly overestimates HRV parameters in both the time and frequency domains due to both the
amplification of HRV oscillations as well as contributions from HRV-independent rhythms
affecting pre-ejection time and pulse transit time. In particular, the mechanical effects of respiration
on venous return, preload, stroke volume, and pulse pressure are the likely explanation for the
HRV-independent centered in the respiratory frequency range. While robust correlations and
moderate to high agreement were found between the changes in time- and absolute frequencydomain PRV and HRV parameters after autonomic blockade, most non-linear parameters showed
very poor agreement after administration of autonomic blockers. Thus, invasively acquired PRV is
likely an acceptale surrogate for HRV except when non-linear measures are a primary endpoint or
when HRV is greatly reduced so that HRV-independent oscillations in the respiratory frequency
range predominate. Because of the fact that the acceptable difference between two methods is
application-specific, we encourage investigators planning to use PRV as a surrogate for HRV and
readers trying to interpret studies in which PRV was performed as a surrogate for HRV to use the
data in this chapter provided to assess the acceptability on a case-by-case basis.
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Main Finding III: The Sympathetic Nervous System Participates in the
Physiological Control of Renal Blood Flow
Similar to other vascular beds, the renal vasculature is under dynamic control by the sympathetic
nervous system. This has been shown clearly by studies in unilaterally denervated conscious
rabbits instrumented with bilateral renal flow probes. When analyzed by time-varying pressureflow analysis, the INV kidney shows a clear vasoconstrictive, baroreflex influence in the LF
consistent with active sympathetic control. The DNx kidney, while experiencing the same
perfusion pressure, has no control mechanism present in this frequency range. This contradicts
the long-held dogma that the renal nerves are silent in the physiological control of RBF, exerting
vasoconstriction only in the context of disease or experimental stimuli. Further examination of
this dogma shows that it relies on an underestimation of the powerful renal autoregulatory
mechanisms, TGF and MR. This technique for the detection of sympathetic vasomotion has
clinical implications in the setting of therapeutic renal denervation, chronic autonomic disease,
and hemodynamic monitoring.
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Interactions Between Main Findings: Reflections and Perspectives
The primary aim of my dissertation was focused on the role of Rho kinase as a functional
mediator of the autonomic effects of AngII (Objective I), and it is this aim which occupied the vast
majority of our time and discussion in supervisory committee meetings. The committee members
all contributed in valuable ways. As evidence for this point, the study recently received largely
positive reviews from the journal Hypertension (as of this writing), and the thing that struck me the
most upon receiving the reviews was the similarity between the reviewer comments and the
feedback from my supervisory committee. This shows how valuable these meetings have been for
the development not only of me as a scientist but also of this project, and I am very grateful for the
input and involvement of each of the committee members in this process.
The interplay between Objective I and the others relates mostly to the theme of autonomic
neurophysiology and our motivation to make meaningful contributions to the field, be it at the level
of molecular mechanism, method validation, or novel biomarker. I will briefly describe the genesis
of these objectives and potential interactions which would be extremely interesting to investigate
further. These objectives stem from Dr. Zucker’s very open and encouraging disposition toward
fostering my involvement in projects that leveraged my engineering background and interests.
Objectives II and III were directed at the validation and development of methods for assessing
autonomic control, and both objectives were born out of questions and struggles faced in our
laboratory.
Objective II arose out of a simple question Dr. Zucker posed during a lab meeting. We
routinely record AP in rats and mice but rarely are these animals instrumented with EKG telemetry,
and several of my former labmates were interested in performing PRV analysis using the AP signal.
Dr. Zucker asked if this was an acceptable surrogate for HRV and suggested that I look at this in
some of my rabbits, which were instrumented with EKG leads and AP telemeters. I was quickly
able to show a strong correlation between HRV and PRV, but, more interestingly, a literature search
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revealed that this question had never been addressed in animals. Despite the existence of many
preclinical studies in which PRV was used as HRV, no one had ever decided to validate this
assumption. This contrasted sharply with the clinical literature, where I could find many studies
investigating the acceptability of using finger plethysmography instead of EKG (it is uncommon
for invasive AP catheters to be more convenient than EKG in the clinic). It seemed like we had
found a significant gap in the literature and that our contribution would be useful not just to our lab
but to others. We devised some additional simple experiments to better assess the underlying
autonomic contributions to PRV and quickly executed the study, sparking my interest in the study
of cardiovascular variability.
Objective III was born out of the frustrating experience of performing conscious recordings
of RSNA in chronically instrumented rabbits. The delicate balance of making electrical contact
with the renal sympathetic nerves without strangulating these fragile visceral fibers makes this a
very difficult process. However, when everything works, the interplay between AP and RSNA in
a healthy, conscious rabbit is reminiscent of a symphony. While these RSNA experiments were
ongoing, we frequently discussed the assessment and quantification of sympathetic nerve activity,
and Dr. Zucker had always expressed a desire for me to develop a new way to quantify RSNA. I
was interested in using signals that worked more consistently and for longer durations; RBF was
one such signal. We happened to have RBF data from INV and DNx kidneys, which would serve
as an interesting all-or-none approach to assessing RSNA using RBF. We decided to compare the
RBF between INV and DNx kidneys, uncovering a sympathetic signature in the RBF control of
INV kidneys. We instrumented more rabbits with RBF probes and found the same result, indicating
a clear role for the renal sympathetic nerves in the regulation of RBF which was completely
contrary to the canonical view that the renal nerves were quiescent controllers of RBF. The
investigation of the primary evidence for this dogma was a very disillusioning experience for me,
and it forced me to confront a lot of very important issues that are rampant in biomedical
science149,150. It was on this background that we performed the studies in Chapter III in a blinded
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fashion and leveraged new tools geared toward improving reproducibility. It is my hope that, in the
spirit of the openness of science, we are able to publish not only the findings but the dataset and
analysis software, so that others may scrutinize and re-analyze the data to make their own
conclusions.
While the different objectives share themes and motivations, I’d like to dedicate a few
paragraphs to some of the direct links between the objectives that went unexplored in this
dissertation but would have been very interesting to investigate in hindsight.
The first is the interaction between the central AngII-mediated cardiac sympatho-excitation
demonstrated in Main Finding I and the relationship between HRV and PRV in Main Finding II.
Since we were not inducing CHF in these studies, it became difficult to justify instrumenting rabbits
with epicardial pacing leads, which requires an invasive thoracotomy procedure. It would have
been interesting, however, to see if the relationship between HRV and PRV were different in a
disease model with chronically elevated cardiac sympathetic tone. One might imagine that the
additional contribution of contractility to HRV-independent PRV rhythms would be exaggerated,
and the response to metoprolol in this context would have been particularly compelling.
Similarly, recording RBF in the rabbits used in Objective I would have yielded very
important insights. For rabbits in the within-subjects cohort, this could have provided perspective
into renal sympathetic outflow beyond the volume status studies, which are admittedly quite
indirect. This data would also have provided valuable insight into how the sympathetic signature
changes in the setting of chronic renal sympatho-excitation with sympathetic baroreflex
dysfunction in a powerful, within-subjects design.
For rabbits in the between-subjects cohort, the addition of RSNA to the AP-RBF analysis
would have served as a very important additional input to the system, which could have been
leveraged to perform sophisticated multivariate analysis. One would hypothesize that by taking into
account RSNA, the AP-RBF transfer function would be the same for INV and DNx kidneys. This
would be a very important finding in support of the system postulated by Main Finding II. While
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others have performed recordings of AP, RSNA, and RBF in the same animal, the results of these
studies are often illogical (e.g., one study suggests that 90% of RBF variance can be explained by
AP and another 90% of RBF variance can be explained by RSNA). Our multivariate approach and
expertise could do a better job of characterizing the physiology.
In summary, each of these objectives made a formative contribution to my training as a
nascent scientist. Objective I was my first experience in hypothesis generation, disease model
testing, grant writing, IACUC protocol writing, and conscious animal experiments. Objective II
was my first experience writing a manuscript as a first-author and bearing the critiques of the peer
review process in that role. Objective III, because of its relevance to the burgeoning field of
therapeutic renal denervation, has garnered considerable clinical and industry interest, teaching me
about technology transfer.

Each of these objectives emphasized to me the importance of

environment, collaboration, luck, patience, and persistence, and these are important lessons that I
will not forget as I continue my training to become a physician-scientist.
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Table 1 – Indices of HRV and PRV derived from the systolic maximum fiducial point for 30 baseline
recordings
Category
Time Domain

PRV

Heart rate (bpm)

187 ± 4

187 ± 4

-0.06 ± 0.22

27/30***

0.999

SDNN (ms)

26.8 ± 2.6

27.8 ± 2.6

-4.56 ± 4.46

29/30***

0.996

RMSSD (ms)

25.1 ± 3.1

27.1 ± 3.1

-15.2 ± 20.9

27/30***

0.970

847 ± 165

890 ±174

-7.73 ± 9.08

28/30***

0.991

299 ± 55.7

302 ±58

-2.2 ± 19.6

19/30

0.894

LF Power (ms )

102 ± 18

106 ±18

-5.5 ± 19.1

28/30***

0.955

LF Power (nu)

25.8 ± 2.5

23.3 ± 2.0

5.8 ± 22.6

23/30*

0.881

HF Power (ms )

444 ± 103

480 ±108

-20.2 ± 23.0

28/30***

0.992

HF Power (nu)

73.6 ± 2.5

76.2 ±2.1

-4.97 ± 9.74

23/30*

0.875

8.3 ± 30.3

23/30*

0.866

2

2

VLF Power (ms )
2

2

LF/HF Ratio

Non-linear

r2

HRV

Total Power (ms )

Frequency Domain

Bland-Altman
Bias
Interval (%) Consistency

Index

0.413 ± 0.062 0.336 ± 0.041

MSE∑1-39

29.9 ± 0.7

31.0 ± 0.8

-3.91 ± 9.23

16/30

0.921

Shannon Entropy

3.81 ± 0.09

3.71 ± 0.09

2.48 ± 3.19

25/30**

0.948

Approximate Entropy

1.24 ± 0.04

1.40 ± 0.05

-14.0 ± 15.1

29/30***

0.841

-8.52 ± 9.55

29/30***

0.813

7.4 ±13.9

23/30*

0.370

2.09 ± 6.03

23/30*

0.907

Sample Entropy
1.26 ± 0.06
1.33 ± 0.027
DFA short-term (α1) 0.949 ± 0.032 0.865 ± 0.024
DFA long-term (α2) 0.948 ± 0.034 0.926 ± 0.033

Values are displayed as mean ± SEM, Bland-Altman intervals (mean bias ± 95% limits of agreement), bias
consistency, and pairwise coefficient of determination (r2) between HRV and PRV values. * p < 0.05, ** p
< 0.01, *** p < 0.001 by Pearson’s χ² test.
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Table 2 – Indices of HRV and PRV derived from the diastolic minimum fiducial point for 30 baseline
recordings
Category
Time Domain

Index

HRV

PRV

Heart rate (bpm)

187 ± 4

187 ± 4

SDNN (ms)

26.8 ± 2.6

RMSSD (ms)

25.1 ± 3.1
2

Total Power (ms )
2

VLF Power (ms )
2

Frequency Domain

r2

-0.18 ± 0.44

27/30***

0.999

28.4 ± 2.8

-7.0 ± 20.6

26/30***

0.887

29.6 ± 3.7

-26.0 ± 59.0

20/30

0.673

847 ± 165

917 ± 178

-12.3 ±45.1

22/30*

0.918

299 ± 55.7

293 ± 57

1.5 ±22.8

17/30

0.892

LF Power (ms )

102 ± 18

101 ± 18

-1.0 ± 22.2

23/30*

0.947

LF Power (nu)

25.8 ± 2.5

23.4 ± 2.4

3.7 ± 41.6

20/30

0.585

HF Power (ms )

444 ± 103

520 ± 115

-37 ± 103

23/30*

0.833

HF Power (nu)

73.6 ± 2.5

76.0 ± 2.5

-4.5 ± 14.6

20/30

0.577

0.4 ± 71.4

20/30

0.664

2

LF/HF Ratio
MSE∑1-39

Non-linear

Bland-Altman
Bias
Interval (%) Consistency

0.413 ± 0.062 0.363 ± 0.058
29.9 ± 0.7

30.4 ± 0.9

-8.1 ± 12.3

17/30

0.762

Shannon Entropy

3.81 ± 0.09

3.71 ± 0.076

2.17 ± 6.01

21/30*

0.792

Approximate Entropy

1.24 ± 0.04

1.26 ± 0.052

-1.35 ± 8.20

20/30

0.921

Sample Entropy
1.26 ± 0.06
1.24 ± 0.03
DFA short-term (α1) 0.949 ± 0.032 0.831 ± 0.036
DFA long-term (α2) 0.948 ± 0.034 0.929 ± 0.035

-0.90 ±5.05

20/30

0.922

11.1 ± 19.7

23/30*

0.213

1.87 ± 8.77

21/30*

0.808

Values are displayed as mean ± SEM, Bland-Altman intervals (mean bias ± 95% limits of agreement), bias
consistency, and pairwise coefficient of determination (r2) between HRV and PRV values. * p < 0.05, ** p
< 0.01, *** p < 0.001 by Pearson’s χ² test.

